Autologous Induced Stem-Cell–Derived Retinal Cells for Macular Degeneration

A goal of regenerative medicine is to use induced pluripotent stem cells to generate an autologous graft for transplantation. This study tests the feasibility of the approach to treat age-related macular degeneration. Age-related macular degeneration (AMD) is one of the most prevalent retinal diseas...

Full description

Saved in:
Bibliographic Details
Published inThe New England journal of medicine Vol. 376; no. 11; pp. 1038 - 1046
Main Authors Mandai, Michiko, Watanabe, Akira, Kurimoto, Yasuo, Hirami, Yasuhiko, Morinaga, Chikako, Daimon, Takashi, Fujihara, Masashi, Akimaru, Hiroshi, Sakai, Noriko, Shibata, Yumiko, Terada, Motoki, Nomiya, Yui, Tanishima, Shigeki, Nakamura, Masahiro, Kamao, Hiroyuki, Sugita, Sunao, Onishi, Akishi, Ito, Tomoko, Fujita, Kanako, Kawamata, Shin, Go, Masahiro J, Shinohara, Chikara, Hata, Ken-ichiro, Sawada, Masanori, Yamamoto, Midori, Ohta, Sachiko, Ohara, Yasuo, Yoshida, Kenichi, Kuwahara, Junko, Kitano, Yuko, Amano, Naoki, Umekage, Masafumi, Kitaoka, Fumiyo, Tanaka, Azusa, Okada, Chihiro, Takasu, Naoko, Ogawa, Seishi, Yamanaka, Shinya, Takahashi, Masayo
Format Journal Article
LanguageEnglish
Published United States Massachusetts Medical Society 16.03.2017
SeriesBrief Report
Subjects
Acuity
Age
Aged
Autografts
Biomedical research
Cell Culture Techniques
Cell Differentiation
Clinical trials
Developmental biology
Edema
Feasibility Studies
Female
Fibroblasts
Genomes
Grants
Hospitals
Humans
Induced Pluripotent Stem Cells - cytology
Macular degeneration
Macular Degeneration - therapy
Male
Photoreceptors
Pluripotency
R&D
Regenerative medicine
Research & development
Retina
Retinal Pigment Epithelium - cytology
Retinal Pigment Epithelium - transplantation
Skin
Stem cells
Surgery
Transplantation
Transplantation, Autologous
Vascular endothelial growth factor
Japan
Online AccessGet full text

Cover

Abstract A goal of regenerative medicine is to use induced pluripotent stem cells to generate an autologous graft for transplantation. This study tests the feasibility of the approach to treat age-related macular degeneration. Age-related macular degeneration (AMD) is one of the most prevalent retinal diseases that threaten vision in older populations in developed countries. 1 – 4 Neovascular (also called “wet”) AMD is more prevalent than atrophic (or “dry”) AMD in Japan 5 and is associated with the ectopic development of a choroidal neovascular membrane in the subretinal space of the center of the retina (the macula). Physical disruption and functional impairment of the retinal pigment epithelium (RPE), a monolayer sheet of cells that supports the overlying photoreceptors and underlying choroidal vasculature, occur in the course of wet AMD. 6 Current treatments of AMD that involve the . . .
AbstractList We assessed the feasibility of transplanting a sheet of retinal pigment epithelial (RPE) cells differentiated from induced pluripotent stem cells (iPSCs) in a patient with neovascular age-related macular degeneration. The iPSCs were generated from skin fibroblasts obtained from two patients with advanced neovascular age-related macular degeneration and were differentiated into RPE cells. The RPE cells and the iPSCs from which they were derived were subject to extensive testing. A surgery that included the removal of the neovascular membrane and transplantation of the autologous iPSC-derived RPE cell sheet under the retina was performed in one of the patients. At 1 year after surgery, the transplanted sheet remained intact, best corrected visual acuity had not improved or worsened, and cystoid macular edema was present. (Funded by Highway Program for Realization of Regenerative Medicine and others; University Hospital Medical Information Network Clinical Trials Registry [UMIN-CTR] number, UMIN000011929 .).We assessed the feasibility of transplanting a sheet of retinal pigment epithelial (RPE) cells differentiated from induced pluripotent stem cells (iPSCs) in a patient with neovascular age-related macular degeneration. The iPSCs were generated from skin fibroblasts obtained from two patients with advanced neovascular age-related macular degeneration and were differentiated into RPE cells. The RPE cells and the iPSCs from which they were derived were subject to extensive testing. A surgery that included the removal of the neovascular membrane and transplantation of the autologous iPSC-derived RPE cell sheet under the retina was performed in one of the patients. At 1 year after surgery, the transplanted sheet remained intact, best corrected visual acuity had not improved or worsened, and cystoid macular edema was present. (Funded by Highway Program for Realization of Regenerative Medicine and others; University Hospital Medical Information Network Clinical Trials Registry [UMIN-CTR] number, UMIN000011929 .).
We assessed the feasibility of transplanting a sheet of retinal pigment epithelial (RPE) cells differentiated from induced pluripotent stem cells (iPSCs) in a patient with neovascular age-related macular degeneration. The iPSCs were generated from skin fibroblasts obtained from two patients with advanced neovascular age-related macular degeneration and were differentiated into RPE cells. The RPE cells and the iPSCs from which they were derived were subject to extensive testing. A surgery that included the removal of the neovascular membrane and transplantation of the autologous iPSC-derived RPE cell sheet under the retina was performed in one of the patients. At 1 year after surgery, the transplanted sheet remained intact, best corrected visual acuity had not improved or worsened, and cystoid macular edema was present. (Funded by Highway Program for Realization of Regenerative Medicine and others; University Hospital Medical Information Network Clinical Trials Registry [UMIN-CTR] number, UMIN000011929.)
A goal of regenerative medicine is to use induced pluripotent stem cells to generate an autologous graft for transplantation. This study tests the feasibility of the approach to treat age-related macular degeneration. Age-related macular degeneration (AMD) is one of the most prevalent retinal diseases that threaten vision in older populations in developed countries. 1 – 4 Neovascular (also called “wet”) AMD is more prevalent than atrophic (or “dry”) AMD in Japan 5 and is associated with the ectopic development of a choroidal neovascular membrane in the subretinal space of the center of the retina (the macula). Physical disruption and functional impairment of the retinal pigment epithelium (RPE), a monolayer sheet of cells that supports the overlying photoreceptors and underlying choroidal vasculature, occur in the course of wet AMD. 6 Current treatments of AMD that involve the . . .
Author Terada, Motoki
Ohara, Yasuo
Takasu, Naoko
Ogawa, Seishi
Fujita, Kanako
Kitaoka, Fumiyo
Ohta, Sachiko
Sawada, Masanori
Yamanaka, Shinya
Umekage, Masafumi
Kuwahara, Junko
Nomiya, Yui
Tanaka, Azusa
Tanishima, Shigeki
Yamamoto, Midori
Morinaga, Chikako
Ito, Tomoko
Kamao, Hiroyuki
Nakamura, Masahiro
Kawamata, Shin
Shinohara, Chikara
Okada, Chihiro
Akimaru, Hiroshi
Kitano, Yuko
Shibata, Yumiko
Onishi, Akishi
Go, Masahiro J
Kurimoto, Yasuo
Daimon, Takashi
Sugita, Sunao
Amano, Naoki
Hata, Ken-ichiro
Yoshida, Kenichi
Watanabe, Akira
Sakai, Noriko
Mandai, Michiko
Fujihara, Masashi
Hirami, Yasuhiko
Takahashi, Masayo
Author_xml – sequence: 1
  givenname: Michiko
  surname: Mandai
  fullname: Mandai, Michiko
  organization: From the Division of Ophthalmology, Institute of Biomedical Research and Innovation Hospital, Foundation for Biomedical Research and Innovation (M.M., Y. Kurimoto, Y.H., M.F., M.Y., S. Ohta, M. Takahashi), Laboratory for Retinal Regeneration, RIKEN Center for Developmental Biology (M.M., C.M., H.A., N.S., Y.S., M. Terada, H.K., S.S., A.O., M.Y., M. Takahashi), the Department of Ophthalmology, Kobe City Medical Center General Hospital (Y.Kurimoto, Y.H., M.F.), the Department of Clinical Trial Management, Institute of Biomedical Research and Innovation Hospital, Foundation for Biomedical Research and Innovation (T.I., K.F.), and Research and Development Center for Cell Therapy, Foundation for Biomedical Research and Innovation (S.K., M.J.G.), Kobe, Center for iPS Cell Research and Application (CiRA) (A.W., Y.N., M.N., J.K., Y. Kitano, N.A., M.U., F.K., A.T., N.T., S.Y.), Institute for Integrated Cell-Material Sciences (iCeMS) (A.W.), and Department of Pathology and Tumor Biology, Graduate School of Medicine (K.Y., S. Ogawa), Kyoto University, Kyoto, the Department of Biostatistics, Hyogo College of Medicine, Nishinomiya (T.D.), Platform of Therapeutics for Rare Disease, National Institutes of Biomedical Innovation, Health, and Nutrition, Ibaraki (H.A.), Mitsubishi Space Software, Tokyo (S.T., Y.O., C.O.), the Department of Ophthalmology, Kawasaki Medical School, Kurashiki (H.K.), Japan Tissue Engineering, Gamagori (C.S., K.H.), and HEALIOS K.K., Tokyo (M.S.) — all in Japan; and Gladstone Institute of Cardiovascular Disease, San Francisco (S.Y.)
– sequence: 2
  givenname: Akira
  surname: Watanabe
  fullname: Watanabe, Akira
  organization: From the Division of Ophthalmology, Institute of Biomedical Research and Innovation Hospital, Foundation for Biomedical Research and Innovation (M.M., Y. Kurimoto, Y.H., M.F., M.Y., S. Ohta, M. Takahashi), Laboratory for Retinal Regeneration, RIKEN Center for Developmental Biology (M.M., C.M., H.A., N.S., Y.S., M. Terada, H.K., S.S., A.O., M.Y., M. Takahashi), the Department of Ophthalmology, Kobe City Medical Center General Hospital (Y.Kurimoto, Y.H., M.F.), the Department of Clinical Trial Management, Institute of Biomedical Research and Innovation Hospital, Foundation for Biomedical Research and Innovation (T.I., K.F.), and Research and Development Center for Cell Therapy, Foundation for Biomedical Research and Innovation (S.K., M.J.G.), Kobe, Center for iPS Cell Research and Application (CiRA) (A.W., Y.N., M.N., J.K., Y. Kitano, N.A., M.U., F.K., A.T., N.T., S.Y.), Institute for Integrated Cell-Material Sciences (iCeMS) (A.W.), and Department of Pathology and Tumor Biology, Graduate School of Medicine (K.Y., S. Ogawa), Kyoto University, Kyoto, the Department of Biostatistics, Hyogo College of Medicine, Nishinomiya (T.D.), Platform of Therapeutics for Rare Disease, National Institutes of Biomedical Innovation, Health, and Nutrition, Ibaraki (H.A.), Mitsubishi Space Software, Tokyo (S.T., Y.O., C.O.), the Department of Ophthalmology, Kawasaki Medical School, Kurashiki (H.K.), Japan Tissue Engineering, Gamagori (C.S., K.H.), and HEALIOS K.K., Tokyo (M.S.) — all in Japan; and Gladstone Institute of Cardiovascular Disease, San Francisco (S.Y.)
– sequence: 3
  givenname: Yasuo
  surname: Kurimoto
  fullname: Kurimoto, Yasuo
  organization: From the Division of Ophthalmology, Institute of Biomedical Research and Innovation Hospital, Foundation for Biomedical Research and Innovation (M.M., Y. Kurimoto, Y.H., M.F., M.Y., S. Ohta, M. Takahashi), Laboratory for Retinal Regeneration, RIKEN Center for Developmental Biology (M.M., C.M., H.A., N.S., Y.S., M. Terada, H.K., S.S., A.O., M.Y., M. Takahashi), the Department of Ophthalmology, Kobe City Medical Center General Hospital (Y.Kurimoto, Y.H., M.F.), the Department of Clinical Trial Management, Institute of Biomedical Research and Innovation Hospital, Foundation for Biomedical Research and Innovation (T.I., K.F.), and Research and Development Center for Cell Therapy, Foundation for Biomedical Research and Innovation (S.K., M.J.G.), Kobe, Center for iPS Cell Research and Application (CiRA) (A.W., Y.N., M.N., J.K., Y. Kitano, N.A., M.U., F.K., A.T., N.T., S.Y.), Institute for Integrated Cell-Material Sciences (iCeMS) (A.W.), and Department of Pathology and Tumor Biology, Graduate School of Medicine (K.Y., S. Ogawa), Kyoto University, Kyoto, the Department of Biostatistics, Hyogo College of Medicine, Nishinomiya (T.D.), Platform of Therapeutics for Rare Disease, National Institutes of Biomedical Innovation, Health, and Nutrition, Ibaraki (H.A.), Mitsubishi Space Software, Tokyo (S.T., Y.O., C.O.), the Department of Ophthalmology, Kawasaki Medical School, Kurashiki (H.K.), Japan Tissue Engineering, Gamagori (C.S., K.H.), and HEALIOS K.K., Tokyo (M.S.) — all in Japan; and Gladstone Institute of Cardiovascular Disease, San Francisco (S.Y.)
– sequence: 4
  givenname: Yasuhiko
  surname: Hirami
  fullname: Hirami, Yasuhiko
  organization: From the Division of Ophthalmology, Institute of Biomedical Research and Innovation Hospital, Foundation for Biomedical Research and Innovation (M.M., Y. Kurimoto, Y.H., M.F., M.Y., S. Ohta, M. Takahashi), Laboratory for Retinal Regeneration, RIKEN Center for Developmental Biology (M.M., C.M., H.A., N.S., Y.S., M. Terada, H.K., S.S., A.O., M.Y., M. Takahashi), the Department of Ophthalmology, Kobe City Medical Center General Hospital (Y.Kurimoto, Y.H., M.F.), the Department of Clinical Trial Management, Institute of Biomedical Research and Innovation Hospital, Foundation for Biomedical Research and Innovation (T.I., K.F.), and Research and Development Center for Cell Therapy, Foundation for Biomedical Research and Innovation (S.K., M.J.G.), Kobe, Center for iPS Cell Research and Application (CiRA) (A.W., Y.N., M.N., J.K., Y. Kitano, N.A., M.U., F.K., A.T., N.T., S.Y.), Institute for Integrated Cell-Material Sciences (iCeMS) (A.W.), and Department of Pathology and Tumor Biology, Graduate School of Medicine (K.Y., S. Ogawa), Kyoto University, Kyoto, the Department of Biostatistics, Hyogo College of Medicine, Nishinomiya (T.D.), Platform of Therapeutics for Rare Disease, National Institutes of Biomedical Innovation, Health, and Nutrition, Ibaraki (H.A.), Mitsubishi Space Software, Tokyo (S.T., Y.O., C.O.), the Department of Ophthalmology, Kawasaki Medical School, Kurashiki (H.K.), Japan Tissue Engineering, Gamagori (C.S., K.H.), and HEALIOS K.K., Tokyo (M.S.) — all in Japan; and Gladstone Institute of Cardiovascular Disease, San Francisco (S.Y.)
– sequence: 5
  givenname: Chikako
  surname: Morinaga
  fullname: Morinaga, Chikako
  organization: From the Division of Ophthalmology, Institute of Biomedical Research and Innovation Hospital, Foundation for Biomedical Research and Innovation (M.M., Y. Kurimoto, Y.H., M.F., M.Y., S. Ohta, M. Takahashi), Laboratory for Retinal Regeneration, RIKEN Center for Developmental Biology (M.M., C.M., H.A., N.S., Y.S., M. Terada, H.K., S.S., A.O., M.Y., M. Takahashi), the Department of Ophthalmology, Kobe City Medical Center General Hospital (Y.Kurimoto, Y.H., M.F.), the Department of Clinical Trial Management, Institute of Biomedical Research and Innovation Hospital, Foundation for Biomedical Research and Innovation (T.I., K.F.), and Research and Development Center for Cell Therapy, Foundation for Biomedical Research and Innovation (S.K., M.J.G.), Kobe, Center for iPS Cell Research and Application (CiRA) (A.W., Y.N., M.N., J.K., Y. Kitano, N.A., M.U., F.K., A.T., N.T., S.Y.), Institute for Integrated Cell-Material Sciences (iCeMS) (A.W.), and Department of Pathology and Tumor Biology, Graduate School of Medicine (K.Y., S. Ogawa), Kyoto University, Kyoto, the Department of Biostatistics, Hyogo College of Medicine, Nishinomiya (T.D.), Platform of Therapeutics for Rare Disease, National Institutes of Biomedical Innovation, Health, and Nutrition, Ibaraki (H.A.), Mitsubishi Space Software, Tokyo (S.T., Y.O., C.O.), the Department of Ophthalmology, Kawasaki Medical School, Kurashiki (H.K.), Japan Tissue Engineering, Gamagori (C.S., K.H.), and HEALIOS K.K., Tokyo (M.S.) — all in Japan; and Gladstone Institute of Cardiovascular Disease, San Francisco (S.Y.)
– sequence: 6
  givenname: Takashi
  surname: Daimon
  fullname: Daimon, Takashi
  organization: From the Division of Ophthalmology, Institute of Biomedical Research and Innovation Hospital, Foundation for Biomedical Research and Innovation (M.M., Y. Kurimoto, Y.H., M.F., M.Y., S. Ohta, M. Takahashi), Laboratory for Retinal Regeneration, RIKEN Center for Developmental Biology (M.M., C.M., H.A., N.S., Y.S., M. Terada, H.K., S.S., A.O., M.Y., M. Takahashi), the Department of Ophthalmology, Kobe City Medical Center General Hospital (Y.Kurimoto, Y.H., M.F.), the Department of Clinical Trial Management, Institute of Biomedical Research and Innovation Hospital, Foundation for Biomedical Research and Innovation (T.I., K.F.), and Research and Development Center for Cell Therapy, Foundation for Biomedical Research and Innovation (S.K., M.J.G.), Kobe, Center for iPS Cell Research and Application (CiRA) (A.W., Y.N., M.N., J.K., Y. Kitano, N.A., M.U., F.K., A.T., N.T., S.Y.), Institute for Integrated Cell-Material Sciences (iCeMS) (A.W.), and Department of Pathology and Tumor Biology, Graduate School of Medicine (K.Y., S. Ogawa), Kyoto University, Kyoto, the Department of Biostatistics, Hyogo College of Medicine, Nishinomiya (T.D.), Platform of Therapeutics for Rare Disease, National Institutes of Biomedical Innovation, Health, and Nutrition, Ibaraki (H.A.), Mitsubishi Space Software, Tokyo (S.T., Y.O., C.O.), the Department of Ophthalmology, Kawasaki Medical School, Kurashiki (H.K.), Japan Tissue Engineering, Gamagori (C.S., K.H.), and HEALIOS K.K., Tokyo (M.S.) — all in Japan; and Gladstone Institute of Cardiovascular Disease, San Francisco (S.Y.)
– sequence: 7
  givenname: Masashi
  surname: Fujihara
  fullname: Fujihara, Masashi
  organization: From the Division of Ophthalmology, Institute of Biomedical Research and Innovation Hospital, Foundation for Biomedical Research and Innovation (M.M., Y. Kurimoto, Y.H., M.F., M.Y., S. Ohta, M. Takahashi), Laboratory for Retinal Regeneration, RIKEN Center for Developmental Biology (M.M., C.M., H.A., N.S., Y.S., M. Terada, H.K., S.S., A.O., M.Y., M. Takahashi), the Department of Ophthalmology, Kobe City Medical Center General Hospital (Y.Kurimoto, Y.H., M.F.), the Department of Clinical Trial Management, Institute of Biomedical Research and Innovation Hospital, Foundation for Biomedical Research and Innovation (T.I., K.F.), and Research and Development Center for Cell Therapy, Foundation for Biomedical Research and Innovation (S.K., M.J.G.), Kobe, Center for iPS Cell Research and Application (CiRA) (A.W., Y.N., M.N., J.K., Y. Kitano, N.A., M.U., F.K., A.T., N.T., S.Y.), Institute for Integrated Cell-Material Sciences (iCeMS) (A.W.), and Department of Pathology and Tumor Biology, Graduate School of Medicine (K.Y., S. Ogawa), Kyoto University, Kyoto, the Department of Biostatistics, Hyogo College of Medicine, Nishinomiya (T.D.), Platform of Therapeutics for Rare Disease, National Institutes of Biomedical Innovation, Health, and Nutrition, Ibaraki (H.A.), Mitsubishi Space Software, Tokyo (S.T., Y.O., C.O.), the Department of Ophthalmology, Kawasaki Medical School, Kurashiki (H.K.), Japan Tissue Engineering, Gamagori (C.S., K.H.), and HEALIOS K.K., Tokyo (M.S.) — all in Japan; and Gladstone Institute of Cardiovascular Disease, San Francisco (S.Y.)
– sequence: 8
  givenname: Hiroshi
  surname: Akimaru
  fullname: Akimaru, Hiroshi
  organization: From the Division of Ophthalmology, Institute of Biomedical Research and Innovation Hospital, Foundation for Biomedical Research and Innovation (M.M., Y. Kurimoto, Y.H., M.F., M.Y., S. Ohta, M. Takahashi), Laboratory for Retinal Regeneration, RIKEN Center for Developmental Biology (M.M., C.M., H.A., N.S., Y.S., M. Terada, H.K., S.S., A.O., M.Y., M. Takahashi), the Department of Ophthalmology, Kobe City Medical Center General Hospital (Y.Kurimoto, Y.H., M.F.), the Department of Clinical Trial Management, Institute of Biomedical Research and Innovation Hospital, Foundation for Biomedical Research and Innovation (T.I., K.F.), and Research and Development Center for Cell Therapy, Foundation for Biomedical Research and Innovation (S.K., M.J.G.), Kobe, Center for iPS Cell Research and Application (CiRA) (A.W., Y.N., M.N., J.K., Y. Kitano, N.A., M.U., F.K., A.T., N.T., S.Y.), Institute for Integrated Cell-Material Sciences (iCeMS) (A.W.), and Department of Pathology and Tumor Biology, Graduate School of Medicine (K.Y., S. Ogawa), Kyoto University, Kyoto, the Department of Biostatistics, Hyogo College of Medicine, Nishinomiya (T.D.), Platform of Therapeutics for Rare Disease, National Institutes of Biomedical Innovation, Health, and Nutrition, Ibaraki (H.A.), Mitsubishi Space Software, Tokyo (S.T., Y.O., C.O.), the Department of Ophthalmology, Kawasaki Medical School, Kurashiki (H.K.), Japan Tissue Engineering, Gamagori (C.S., K.H.), and HEALIOS K.K., Tokyo (M.S.) — all in Japan; and Gladstone Institute of Cardiovascular Disease, San Francisco (S.Y.)
– sequence: 9
  givenname: Noriko
  surname: Sakai
  fullname: Sakai, Noriko
  organization: From the Division of Ophthalmology, Institute of Biomedical Research and Innovation Hospital, Foundation for Biomedical Research and Innovation (M.M., Y. Kurimoto, Y.H., M.F., M.Y., S. Ohta, M. Takahashi), Laboratory for Retinal Regeneration, RIKEN Center for Developmental Biology (M.M., C.M., H.A., N.S., Y.S., M. Terada, H.K., S.S., A.O., M.Y., M. Takahashi), the Department of Ophthalmology, Kobe City Medical Center General Hospital (Y.Kurimoto, Y.H., M.F.), the Department of Clinical Trial Management, Institute of Biomedical Research and Innovation Hospital, Foundation for Biomedical Research and Innovation (T.I., K.F.), and Research and Development Center for Cell Therapy, Foundation for Biomedical Research and Innovation (S.K., M.J.G.), Kobe, Center for iPS Cell Research and Application (CiRA) (A.W., Y.N., M.N., J.K., Y. Kitano, N.A., M.U., F.K., A.T., N.T., S.Y.), Institute for Integrated Cell-Material Sciences (iCeMS) (A.W.), and Department of Pathology and Tumor Biology, Graduate School of Medicine (K.Y., S. Ogawa), Kyoto University, Kyoto, the Department of Biostatistics, Hyogo College of Medicine, Nishinomiya (T.D.), Platform of Therapeutics for Rare Disease, National Institutes of Biomedical Innovation, Health, and Nutrition, Ibaraki (H.A.), Mitsubishi Space Software, Tokyo (S.T., Y.O., C.O.), the Department of Ophthalmology, Kawasaki Medical School, Kurashiki (H.K.), Japan Tissue Engineering, Gamagori (C.S., K.H.), and HEALIOS K.K., Tokyo (M.S.) — all in Japan; and Gladstone Institute of Cardiovascular Disease, San Francisco (S.Y.)
– sequence: 10
  givenname: Yumiko
  surname: Shibata
  fullname: Shibata, Yumiko
  organization: From the Division of Ophthalmology, Institute of Biomedical Research and Innovation Hospital, Foundation for Biomedical Research and Innovation (M.M., Y. Kurimoto, Y.H., M.F., M.Y., S. Ohta, M. Takahashi), Laboratory for Retinal Regeneration, RIKEN Center for Developmental Biology (M.M., C.M., H.A., N.S., Y.S., M. Terada, H.K., S.S., A.O., M.Y., M. Takahashi), the Department of Ophthalmology, Kobe City Medical Center General Hospital (Y.Kurimoto, Y.H., M.F.), the Department of Clinical Trial Management, Institute of Biomedical Research and Innovation Hospital, Foundation for Biomedical Research and Innovation (T.I., K.F.), and Research and Development Center for Cell Therapy, Foundation for Biomedical Research and Innovation (S.K., M.J.G.), Kobe, Center for iPS Cell Research and Application (CiRA) (A.W., Y.N., M.N., J.K., Y. Kitano, N.A., M.U., F.K., A.T., N.T., S.Y.), Institute for Integrated Cell-Material Sciences (iCeMS) (A.W.), and Department of Pathology and Tumor Biology, Graduate School of Medicine (K.Y., S. Ogawa), Kyoto University, Kyoto, the Department of Biostatistics, Hyogo College of Medicine, Nishinomiya (T.D.), Platform of Therapeutics for Rare Disease, National Institutes of Biomedical Innovation, Health, and Nutrition, Ibaraki (H.A.), Mitsubishi Space Software, Tokyo (S.T., Y.O., C.O.), the Department of Ophthalmology, Kawasaki Medical School, Kurashiki (H.K.), Japan Tissue Engineering, Gamagori (C.S., K.H.), and HEALIOS K.K., Tokyo (M.S.) — all in Japan; and Gladstone Institute of Cardiovascular Disease, San Francisco (S.Y.)
– sequence: 11
  givenname: Motoki
  surname: Terada
  fullname: Terada, Motoki
  organization: From the Division of Ophthalmology, Institute of Biomedical Research and Innovation Hospital, Foundation for Biomedical Research and Innovation (M.M., Y. Kurimoto, Y.H., M.F., M.Y., S. Ohta, M. Takahashi), Laboratory for Retinal Regeneration, RIKEN Center for Developmental Biology (M.M., C.M., H.A., N.S., Y.S., M. Terada, H.K., S.S., A.O., M.Y., M. Takahashi), the Department of Ophthalmology, Kobe City Medical Center General Hospital (Y.Kurimoto, Y.H., M.F.), the Department of Clinical Trial Management, Institute of Biomedical Research and Innovation Hospital, Foundation for Biomedical Research and Innovation (T.I., K.F.), and Research and Development Center for Cell Therapy, Foundation for Biomedical Research and Innovation (S.K., M.J.G.), Kobe, Center for iPS Cell Research and Application (CiRA) (A.W., Y.N., M.N., J.K., Y. Kitano, N.A., M.U., F.K., A.T., N.T., S.Y.), Institute for Integrated Cell-Material Sciences (iCeMS) (A.W.), and Department of Pathology and Tumor Biology, Graduate School of Medicine (K.Y., S. Ogawa), Kyoto University, Kyoto, the Department of Biostatistics, Hyogo College of Medicine, Nishinomiya (T.D.), Platform of Therapeutics for Rare Disease, National Institutes of Biomedical Innovation, Health, and Nutrition, Ibaraki (H.A.), Mitsubishi Space Software, Tokyo (S.T., Y.O., C.O.), the Department of Ophthalmology, Kawasaki Medical School, Kurashiki (H.K.), Japan Tissue Engineering, Gamagori (C.S., K.H.), and HEALIOS K.K., Tokyo (M.S.) — all in Japan; and Gladstone Institute of Cardiovascular Disease, San Francisco (S.Y.)
– sequence: 12
  givenname: Yui
  surname: Nomiya
  fullname: Nomiya, Yui
  organization: From the Division of Ophthalmology, Institute of Biomedical Research and Innovation Hospital, Foundation for Biomedical Research and Innovation (M.M., Y. Kurimoto, Y.H., M.F., M.Y., S. Ohta, M. Takahashi), Laboratory for Retinal Regeneration, RIKEN Center for Developmental Biology (M.M., C.M., H.A., N.S., Y.S., M. Terada, H.K., S.S., A.O., M.Y., M. Takahashi), the Department of Ophthalmology, Kobe City Medical Center General Hospital (Y.Kurimoto, Y.H., M.F.), the Department of Clinical Trial Management, Institute of Biomedical Research and Innovation Hospital, Foundation for Biomedical Research and Innovation (T.I., K.F.), and Research and Development Center for Cell Therapy, Foundation for Biomedical Research and Innovation (S.K., M.J.G.), Kobe, Center for iPS Cell Research and Application (CiRA) (A.W., Y.N., M.N., J.K., Y. Kitano, N.A., M.U., F.K., A.T., N.T., S.Y.), Institute for Integrated Cell-Material Sciences (iCeMS) (A.W.), and Department of Pathology and Tumor Biology, Graduate School of Medicine (K.Y., S. Ogawa), Kyoto University, Kyoto, the Department of Biostatistics, Hyogo College of Medicine, Nishinomiya (T.D.), Platform of Therapeutics for Rare Disease, National Institutes of Biomedical Innovation, Health, and Nutrition, Ibaraki (H.A.), Mitsubishi Space Software, Tokyo (S.T., Y.O., C.O.), the Department of Ophthalmology, Kawasaki Medical School, Kurashiki (H.K.), Japan Tissue Engineering, Gamagori (C.S., K.H.), and HEALIOS K.K., Tokyo (M.S.) — all in Japan; and Gladstone Institute of Cardiovascular Disease, San Francisco (S.Y.)
– sequence: 13
  givenname: Shigeki
  surname: Tanishima
  fullname: Tanishima, Shigeki
  organization: From the Division of Ophthalmology, Institute of Biomedical Research and Innovation Hospital, Foundation for Biomedical Research and Innovation (M.M., Y. Kurimoto, Y.H., M.F., M.Y., S. Ohta, M. Takahashi), Laboratory for Retinal Regeneration, RIKEN Center for Developmental Biology (M.M., C.M., H.A., N.S., Y.S., M. Terada, H.K., S.S., A.O., M.Y., M. Takahashi), the Department of Ophthalmology, Kobe City Medical Center General Hospital (Y.Kurimoto, Y.H., M.F.), the Department of Clinical Trial Management, Institute of Biomedical Research and Innovation Hospital, Foundation for Biomedical Research and Innovation (T.I., K.F.), and Research and Development Center for Cell Therapy, Foundation for Biomedical Research and Innovation (S.K., M.J.G.), Kobe, Center for iPS Cell Research and Application (CiRA) (A.W., Y.N., M.N., J.K., Y. Kitano, N.A., M.U., F.K., A.T., N.T., S.Y.), Institute for Integrated Cell-Material Sciences (iCeMS) (A.W.), and Department of Pathology and Tumor Biology, Graduate School of Medicine (K.Y., S. Ogawa), Kyoto University, Kyoto, the Department of Biostatistics, Hyogo College of Medicine, Nishinomiya (T.D.), Platform of Therapeutics for Rare Disease, National Institutes of Biomedical Innovation, Health, and Nutrition, Ibaraki (H.A.), Mitsubishi Space Software, Tokyo (S.T., Y.O., C.O.), the Department of Ophthalmology, Kawasaki Medical School, Kurashiki (H.K.), Japan Tissue Engineering, Gamagori (C.S., K.H.), and HEALIOS K.K., Tokyo (M.S.) — all in Japan; and Gladstone Institute of Cardiovascular Disease, San Francisco (S.Y.)
– sequence: 14
  givenname: Masahiro
  surname: Nakamura
  fullname: Nakamura, Masahiro
  organization: From the Division of Ophthalmology, Institute of Biomedical Research and Innovation Hospital, Foundation for Biomedical Research and Innovation (M.M., Y. Kurimoto, Y.H., M.F., M.Y., S. Ohta, M. Takahashi), Laboratory for Retinal Regeneration, RIKEN Center for Developmental Biology (M.M., C.M., H.A., N.S., Y.S., M. Terada, H.K., S.S., A.O., M.Y., M. Takahashi), the Department of Ophthalmology, Kobe City Medical Center General Hospital (Y.Kurimoto, Y.H., M.F.), the Department of Clinical Trial Management, Institute of Biomedical Research and Innovation Hospital, Foundation for Biomedical Research and Innovation (T.I., K.F.), and Research and Development Center for Cell Therapy, Foundation for Biomedical Research and Innovation (S.K., M.J.G.), Kobe, Center for iPS Cell Research and Application (CiRA) (A.W., Y.N., M.N., J.K., Y. Kitano, N.A., M.U., F.K., A.T., N.T., S.Y.), Institute for Integrated Cell-Material Sciences (iCeMS) (A.W.), and Department of Pathology and Tumor Biology, Graduate School of Medicine (K.Y., S. Ogawa), Kyoto University, Kyoto, the Department of Biostatistics, Hyogo College of Medicine, Nishinomiya (T.D.), Platform of Therapeutics for Rare Disease, National Institutes of Biomedical Innovation, Health, and Nutrition, Ibaraki (H.A.), Mitsubishi Space Software, Tokyo (S.T., Y.O., C.O.), the Department of Ophthalmology, Kawasaki Medical School, Kurashiki (H.K.), Japan Tissue Engineering, Gamagori (C.S., K.H.), and HEALIOS K.K., Tokyo (M.S.) — all in Japan; and Gladstone Institute of Cardiovascular Disease, San Francisco (S.Y.)
– sequence: 15
  givenname: Hiroyuki
  surname: Kamao
  fullname: Kamao, Hiroyuki
  organization: From the Division of Ophthalmology, Institute of Biomedical Research and Innovation Hospital, Foundation for Biomedical Research and Innovation (M.M., Y. Kurimoto, Y.H., M.F., M.Y., S. Ohta, M. Takahashi), Laboratory for Retinal Regeneration, RIKEN Center for Developmental Biology (M.M., C.M., H.A., N.S., Y.S., M. Terada, H.K., S.S., A.O., M.Y., M. Takahashi), the Department of Ophthalmology, Kobe City Medical Center General Hospital (Y.Kurimoto, Y.H., M.F.), the Department of Clinical Trial Management, Institute of Biomedical Research and Innovation Hospital, Foundation for Biomedical Research and Innovation (T.I., K.F.), and Research and Development Center for Cell Therapy, Foundation for Biomedical Research and Innovation (S.K., M.J.G.), Kobe, Center for iPS Cell Research and Application (CiRA) (A.W., Y.N., M.N., J.K., Y. Kitano, N.A., M.U., F.K., A.T., N.T., S.Y.), Institute for Integrated Cell-Material Sciences (iCeMS) (A.W.), and Department of Pathology and Tumor Biology, Graduate School of Medicine (K.Y., S. Ogawa), Kyoto University, Kyoto, the Department of Biostatistics, Hyogo College of Medicine, Nishinomiya (T.D.), Platform of Therapeutics for Rare Disease, National Institutes of Biomedical Innovation, Health, and Nutrition, Ibaraki (H.A.), Mitsubishi Space Software, Tokyo (S.T., Y.O., C.O.), the Department of Ophthalmology, Kawasaki Medical School, Kurashiki (H.K.), Japan Tissue Engineering, Gamagori (C.S., K.H.), and HEALIOS K.K., Tokyo (M.S.) — all in Japan; and Gladstone Institute of Cardiovascular Disease, San Francisco (S.Y.)
– sequence: 16
  givenname: Sunao
  surname: Sugita
  fullname: Sugita, Sunao
  organization: From the Division of Ophthalmology, Institute of Biomedical Research and Innovation Hospital, Foundation for Biomedical Research and Innovation (M.M., Y. Kurimoto, Y.H., M.F., M.Y., S. Ohta, M. Takahashi), Laboratory for Retinal Regeneration, RIKEN Center for Developmental Biology (M.M., C.M., H.A., N.S., Y.S., M. Terada, H.K., S.S., A.O., M.Y., M. Takahashi), the Department of Ophthalmology, Kobe City Medical Center General Hospital (Y.Kurimoto, Y.H., M.F.), the Department of Clinical Trial Management, Institute of Biomedical Research and Innovation Hospital, Foundation for Biomedical Research and Innovation (T.I., K.F.), and Research and Development Center for Cell Therapy, Foundation for Biomedical Research and Innovation (S.K., M.J.G.), Kobe, Center for iPS Cell Research and Application (CiRA) (A.W., Y.N., M.N., J.K., Y. Kitano, N.A., M.U., F.K., A.T., N.T., S.Y.), Institute for Integrated Cell-Material Sciences (iCeMS) (A.W.), and Department of Pathology and Tumor Biology, Graduate School of Medicine (K.Y., S. Ogawa), Kyoto University, Kyoto, the Department of Biostatistics, Hyogo College of Medicine, Nishinomiya (T.D.), Platform of Therapeutics for Rare Disease, National Institutes of Biomedical Innovation, Health, and Nutrition, Ibaraki (H.A.), Mitsubishi Space Software, Tokyo (S.T., Y.O., C.O.), the Department of Ophthalmology, Kawasaki Medical School, Kurashiki (H.K.), Japan Tissue Engineering, Gamagori (C.S., K.H.), and HEALIOS K.K., Tokyo (M.S.) — all in Japan; and Gladstone Institute of Cardiovascular Disease, San Francisco (S.Y.)
– sequence: 17
  givenname: Akishi
  surname: Onishi
  fullname: Onishi, Akishi
  organization: From the Division of Ophthalmology, Institute of Biomedical Research and Innovation Hospital, Foundation for Biomedical Research and Innovation (M.M., Y. Kurimoto, Y.H., M.F., M.Y., S. Ohta, M. Takahashi), Laboratory for Retinal Regeneration, RIKEN Center for Developmental Biology (M.M., C.M., H.A., N.S., Y.S., M. Terada, H.K., S.S., A.O., M.Y., M. Takahashi), the Department of Ophthalmology, Kobe City Medical Center General Hospital (Y.Kurimoto, Y.H., M.F.), the Department of Clinical Trial Management, Institute of Biomedical Research and Innovation Hospital, Foundation for Biomedical Research and Innovation (T.I., K.F.), and Research and Development Center for Cell Therapy, Foundation for Biomedical Research and Innovation (S.K., M.J.G.), Kobe, Center for iPS Cell Research and Application (CiRA) (A.W., Y.N., M.N., J.K., Y. Kitano, N.A., M.U., F.K., A.T., N.T., S.Y.), Institute for Integrated Cell-Material Sciences (iCeMS) (A.W.), and Department of Pathology and Tumor Biology, Graduate School of Medicine (K.Y., S. Ogawa), Kyoto University, Kyoto, the Department of Biostatistics, Hyogo College of Medicine, Nishinomiya (T.D.), Platform of Therapeutics for Rare Disease, National Institutes of Biomedical Innovation, Health, and Nutrition, Ibaraki (H.A.), Mitsubishi Space Software, Tokyo (S.T., Y.O., C.O.), the Department of Ophthalmology, Kawasaki Medical School, Kurashiki (H.K.), Japan Tissue Engineering, Gamagori (C.S., K.H.), and HEALIOS K.K., Tokyo (M.S.) — all in Japan; and Gladstone Institute of Cardiovascular Disease, San Francisco (S.Y.)
– sequence: 18
  givenname: Tomoko
  surname: Ito
  fullname: Ito, Tomoko
  organization: From the Division of Ophthalmology, Institute of Biomedical Research and Innovation Hospital, Foundation for Biomedical Research and Innovation (M.M., Y. Kurimoto, Y.H., M.F., M.Y., S. Ohta, M. Takahashi), Laboratory for Retinal Regeneration, RIKEN Center for Developmental Biology (M.M., C.M., H.A., N.S., Y.S., M. Terada, H.K., S.S., A.O., M.Y., M. Takahashi), the Department of Ophthalmology, Kobe City Medical Center General Hospital (Y.Kurimoto, Y.H., M.F.), the Department of Clinical Trial Management, Institute of Biomedical Research and Innovation Hospital, Foundation for Biomedical Research and Innovation (T.I., K.F.), and Research and Development Center for Cell Therapy, Foundation for Biomedical Research and Innovation (S.K., M.J.G.), Kobe, Center for iPS Cell Research and Application (CiRA) (A.W., Y.N., M.N., J.K., Y. Kitano, N.A., M.U., F.K., A.T., N.T., S.Y.), Institute for Integrated Cell-Material Sciences (iCeMS) (A.W.), and Department of Pathology and Tumor Biology, Graduate School of Medicine (K.Y., S. Ogawa), Kyoto University, Kyoto, the Department of Biostatistics, Hyogo College of Medicine, Nishinomiya (T.D.), Platform of Therapeutics for Rare Disease, National Institutes of Biomedical Innovation, Health, and Nutrition, Ibaraki (H.A.), Mitsubishi Space Software, Tokyo (S.T., Y.O., C.O.), the Department of Ophthalmology, Kawasaki Medical School, Kurashiki (H.K.), Japan Tissue Engineering, Gamagori (C.S., K.H.), and HEALIOS K.K., Tokyo (M.S.) — all in Japan; and Gladstone Institute of Cardiovascular Disease, San Francisco (S.Y.)
– sequence: 19
  givenname: Kanako
  surname: Fujita
  fullname: Fujita, Kanako
  organization: From the Division of Ophthalmology, Institute of Biomedical Research and Innovation Hospital, Foundation for Biomedical Research and Innovation (M.M., Y. Kurimoto, Y.H., M.F., M.Y., S. Ohta, M. Takahashi), Laboratory for Retinal Regeneration, RIKEN Center for Developmental Biology (M.M., C.M., H.A., N.S., Y.S., M. Terada, H.K., S.S., A.O., M.Y., M. Takahashi), the Department of Ophthalmology, Kobe City Medical Center General Hospital (Y.Kurimoto, Y.H., M.F.), the Department of Clinical Trial Management, Institute of Biomedical Research and Innovation Hospital, Foundation for Biomedical Research and Innovation (T.I., K.F.), and Research and Development Center for Cell Therapy, Foundation for Biomedical Research and Innovation (S.K., M.J.G.), Kobe, Center for iPS Cell Research and Application (CiRA) (A.W., Y.N., M.N., J.K., Y. Kitano, N.A., M.U., F.K., A.T., N.T., S.Y.), Institute for Integrated Cell-Material Sciences (iCeMS) (A.W.), and Department of Pathology and Tumor Biology, Graduate School of Medicine (K.Y., S. Ogawa), Kyoto University, Kyoto, the Department of Biostatistics, Hyogo College of Medicine, Nishinomiya (T.D.), Platform of Therapeutics for Rare Disease, National Institutes of Biomedical Innovation, Health, and Nutrition, Ibaraki (H.A.), Mitsubishi Space Software, Tokyo (S.T., Y.O., C.O.), the Department of Ophthalmology, Kawasaki Medical School, Kurashiki (H.K.), Japan Tissue Engineering, Gamagori (C.S., K.H.), and HEALIOS K.K., Tokyo (M.S.) — all in Japan; and Gladstone Institute of Cardiovascular Disease, San Francisco (S.Y.)
– sequence: 20
  givenname: Shin
  surname: Kawamata
  fullname: Kawamata, Shin
  organization: From the Division of Ophthalmology, Institute of Biomedical Research and Innovation Hospital, Foundation for Biomedical Research and Innovation (M.M., Y. Kurimoto, Y.H., M.F., M.Y., S. Ohta, M. Takahashi), Laboratory for Retinal Regeneration, RIKEN Center for Developmental Biology (M.M., C.M., H.A., N.S., Y.S., M. Terada, H.K., S.S., A.O., M.Y., M. Takahashi), the Department of Ophthalmology, Kobe City Medical Center General Hospital (Y.Kurimoto, Y.H., M.F.), the Department of Clinical Trial Management, Institute of Biomedical Research and Innovation Hospital, Foundation for Biomedical Research and Innovation (T.I., K.F.), and Research and Development Center for Cell Therapy, Foundation for Biomedical Research and Innovation (S.K., M.J.G.), Kobe, Center for iPS Cell Research and Application (CiRA) (A.W., Y.N., M.N., J.K., Y. Kitano, N.A., M.U., F.K., A.T., N.T., S.Y.), Institute for Integrated Cell-Material Sciences (iCeMS) (A.W.), and Department of Pathology and Tumor Biology, Graduate School of Medicine (K.Y., S. Ogawa), Kyoto University, Kyoto, the Department of Biostatistics, Hyogo College of Medicine, Nishinomiya (T.D.), Platform of Therapeutics for Rare Disease, National Institutes of Biomedical Innovation, Health, and Nutrition, Ibaraki (H.A.), Mitsubishi Space Software, Tokyo (S.T., Y.O., C.O.), the Department of Ophthalmology, Kawasaki Medical School, Kurashiki (H.K.), Japan Tissue Engineering, Gamagori (C.S., K.H.), and HEALIOS K.K., Tokyo (M.S.) — all in Japan; and Gladstone Institute of Cardiovascular Disease, San Francisco (S.Y.)
– sequence: 21
  givenname: Masahiro J
  surname: Go
  fullname: Go, Masahiro J
  organization: From the Division of Ophthalmology, Institute of Biomedical Research and Innovation Hospital, Foundation for Biomedical Research and Innovation (M.M., Y. Kurimoto, Y.H., M.F., M.Y., S. Ohta, M. Takahashi), Laboratory for Retinal Regeneration, RIKEN Center for Developmental Biology (M.M., C.M., H.A., N.S., Y.S., M. Terada, H.K., S.S., A.O., M.Y., M. Takahashi), the Department of Ophthalmology, Kobe City Medical Center General Hospital (Y.Kurimoto, Y.H., M.F.), the Department of Clinical Trial Management, Institute of Biomedical Research and Innovation Hospital, Foundation for Biomedical Research and Innovation (T.I., K.F.), and Research and Development Center for Cell Therapy, Foundation for Biomedical Research and Innovation (S.K., M.J.G.), Kobe, Center for iPS Cell Research and Application (CiRA) (A.W., Y.N., M.N., J.K., Y. Kitano, N.A., M.U., F.K., A.T., N.T., S.Y.), Institute for Integrated Cell-Material Sciences (iCeMS) (A.W.), and Department of Pathology and Tumor Biology, Graduate School of Medicine (K.Y., S. Ogawa), Kyoto University, Kyoto, the Department of Biostatistics, Hyogo College of Medicine, Nishinomiya (T.D.), Platform of Therapeutics for Rare Disease, National Institutes of Biomedical Innovation, Health, and Nutrition, Ibaraki (H.A.), Mitsubishi Space Software, Tokyo (S.T., Y.O., C.O.), the Department of Ophthalmology, Kawasaki Medical School, Kurashiki (H.K.), Japan Tissue Engineering, Gamagori (C.S., K.H.), and HEALIOS K.K., Tokyo (M.S.) — all in Japan; and Gladstone Institute of Cardiovascular Disease, San Francisco (S.Y.)
– sequence: 22
  givenname: Chikara
  surname: Shinohara
  fullname: Shinohara, Chikara
  organization: From the Division of Ophthalmology, Institute of Biomedical Research and Innovation Hospital, Foundation for Biomedical Research and Innovation (M.M., Y. Kurimoto, Y.H., M.F., M.Y., S. Ohta, M. Takahashi), Laboratory for Retinal Regeneration, RIKEN Center for Developmental Biology (M.M., C.M., H.A., N.S., Y.S., M. Terada, H.K., S.S., A.O., M.Y., M. Takahashi), the Department of Ophthalmology, Kobe City Medical Center General Hospital (Y.Kurimoto, Y.H., M.F.), the Department of Clinical Trial Management, Institute of Biomedical Research and Innovation Hospital, Foundation for Biomedical Research and Innovation (T.I., K.F.), and Research and Development Center for Cell Therapy, Foundation for Biomedical Research and Innovation (S.K., M.J.G.), Kobe, Center for iPS Cell Research and Application (CiRA) (A.W., Y.N., M.N., J.K., Y. Kitano, N.A., M.U., F.K., A.T., N.T., S.Y.), Institute for Integrated Cell-Material Sciences (iCeMS) (A.W.), and Department of Pathology and Tumor Biology, Graduate School of Medicine (K.Y., S. Ogawa), Kyoto University, Kyoto, the Department of Biostatistics, Hyogo College of Medicine, Nishinomiya (T.D.), Platform of Therapeutics for Rare Disease, National Institutes of Biomedical Innovation, Health, and Nutrition, Ibaraki (H.A.), Mitsubishi Space Software, Tokyo (S.T., Y.O., C.O.), the Department of Ophthalmology, Kawasaki Medical School, Kurashiki (H.K.), Japan Tissue Engineering, Gamagori (C.S., K.H.), and HEALIOS K.K., Tokyo (M.S.) — all in Japan; and Gladstone Institute of Cardiovascular Disease, San Francisco (S.Y.)
– sequence: 23
  givenname: Ken-ichiro
  surname: Hata
  fullname: Hata, Ken-ichiro
  organization: From the Division of Ophthalmology, Institute of Biomedical Research and Innovation Hospital, Foundation for Biomedical Research and Innovation (M.M., Y. Kurimoto, Y.H., M.F., M.Y., S. Ohta, M. Takahashi), Laboratory for Retinal Regeneration, RIKEN Center for Developmental Biology (M.M., C.M., H.A., N.S., Y.S., M. Terada, H.K., S.S., A.O., M.Y., M. Takahashi), the Department of Ophthalmology, Kobe City Medical Center General Hospital (Y.Kurimoto, Y.H., M.F.), the Department of Clinical Trial Management, Institute of Biomedical Research and Innovation Hospital, Foundation for Biomedical Research and Innovation (T.I., K.F.), and Research and Development Center for Cell Therapy, Foundation for Biomedical Research and Innovation (S.K., M.J.G.), Kobe, Center for iPS Cell Research and Application (CiRA) (A.W., Y.N., M.N., J.K., Y. Kitano, N.A., M.U., F.K., A.T., N.T., S.Y.), Institute for Integrated Cell-Material Sciences (iCeMS) (A.W.), and Department of Pathology and Tumor Biology, Graduate School of Medicine (K.Y., S. Ogawa), Kyoto University, Kyoto, the Department of Biostatistics, Hyogo College of Medicine, Nishinomiya (T.D.), Platform of Therapeutics for Rare Disease, National Institutes of Biomedical Innovation, Health, and Nutrition, Ibaraki (H.A.), Mitsubishi Space Software, Tokyo (S.T., Y.O., C.O.), the Department of Ophthalmology, Kawasaki Medical School, Kurashiki (H.K.), Japan Tissue Engineering, Gamagori (C.S., K.H.), and HEALIOS K.K., Tokyo (M.S.) — all in Japan; and Gladstone Institute of Cardiovascular Disease, San Francisco (S.Y.)
– sequence: 24
  givenname: Masanori
  surname: Sawada
  fullname: Sawada, Masanori
  organization: From the Division of Ophthalmology, Institute of Biomedical Research and Innovation Hospital, Foundation for Biomedical Research and Innovation (M.M., Y. Kurimoto, Y.H., M.F., M.Y., S. Ohta, M. Takahashi), Laboratory for Retinal Regeneration, RIKEN Center for Developmental Biology (M.M., C.M., H.A., N.S., Y.S., M. Terada, H.K., S.S., A.O., M.Y., M. Takahashi), the Department of Ophthalmology, Kobe City Medical Center General Hospital (Y.Kurimoto, Y.H., M.F.), the Department of Clinical Trial Management, Institute of Biomedical Research and Innovation Hospital, Foundation for Biomedical Research and Innovation (T.I., K.F.), and Research and Development Center for Cell Therapy, Foundation for Biomedical Research and Innovation (S.K., M.J.G.), Kobe, Center for iPS Cell Research and Application (CiRA) (A.W., Y.N., M.N., J.K., Y. Kitano, N.A., M.U., F.K., A.T., N.T., S.Y.), Institute for Integrated Cell-Material Sciences (iCeMS) (A.W.), and Department of Pathology and Tumor Biology, Graduate School of Medicine (K.Y., S. Ogawa), Kyoto University, Kyoto, the Department of Biostatistics, Hyogo College of Medicine, Nishinomiya (T.D.), Platform of Therapeutics for Rare Disease, National Institutes of Biomedical Innovation, Health, and Nutrition, Ibaraki (H.A.), Mitsubishi Space Software, Tokyo (S.T., Y.O., C.O.), the Department of Ophthalmology, Kawasaki Medical School, Kurashiki (H.K.), Japan Tissue Engineering, Gamagori (C.S., K.H.), and HEALIOS K.K., Tokyo (M.S.) — all in Japan; and Gladstone Institute of Cardiovascular Disease, San Francisco (S.Y.)
– sequence: 25
  givenname: Midori
  surname: Yamamoto
  fullname: Yamamoto, Midori
  organization: From the Division of Ophthalmology, Institute of Biomedical Research and Innovation Hospital, Foundation for Biomedical Research and Innovation (M.M., Y. Kurimoto, Y.H., M.F., M.Y., S. Ohta, M. Takahashi), Laboratory for Retinal Regeneration, RIKEN Center for Developmental Biology (M.M., C.M., H.A., N.S., Y.S., M. Terada, H.K., S.S., A.O., M.Y., M. Takahashi), the Department of Ophthalmology, Kobe City Medical Center General Hospital (Y.Kurimoto, Y.H., M.F.), the Department of Clinical Trial Management, Institute of Biomedical Research and Innovation Hospital, Foundation for Biomedical Research and Innovation (T.I., K.F.), and Research and Development Center for Cell Therapy, Foundation for Biomedical Research and Innovation (S.K., M.J.G.), Kobe, Center for iPS Cell Research and Application (CiRA) (A.W., Y.N., M.N., J.K., Y. Kitano, N.A., M.U., F.K., A.T., N.T., S.Y.), Institute for Integrated Cell-Material Sciences (iCeMS) (A.W.), and Department of Pathology and Tumor Biology, Graduate School of Medicine (K.Y., S. Ogawa), Kyoto University, Kyoto, the Department of Biostatistics, Hyogo College of Medicine, Nishinomiya (T.D.), Platform of Therapeutics for Rare Disease, National Institutes of Biomedical Innovation, Health, and Nutrition, Ibaraki (H.A.), Mitsubishi Space Software, Tokyo (S.T., Y.O., C.O.), the Department of Ophthalmology, Kawasaki Medical School, Kurashiki (H.K.), Japan Tissue Engineering, Gamagori (C.S., K.H.), and HEALIOS K.K., Tokyo (M.S.) — all in Japan; and Gladstone Institute of Cardiovascular Disease, San Francisco (S.Y.)
– sequence: 26
  givenname: Sachiko
  surname: Ohta
  fullname: Ohta, Sachiko
  organization: From the Division of Ophthalmology, Institute of Biomedical Research and Innovation Hospital, Foundation for Biomedical Research and Innovation (M.M., Y. Kurimoto, Y.H., M.F., M.Y., S. Ohta, M. Takahashi), Laboratory for Retinal Regeneration, RIKEN Center for Developmental Biology (M.M., C.M., H.A., N.S., Y.S., M. Terada, H.K., S.S., A.O., M.Y., M. Takahashi), the Department of Ophthalmology, Kobe City Medical Center General Hospital (Y.Kurimoto, Y.H., M.F.), the Department of Clinical Trial Management, Institute of Biomedical Research and Innovation Hospital, Foundation for Biomedical Research and Innovation (T.I., K.F.), and Research and Development Center for Cell Therapy, Foundation for Biomedical Research and Innovation (S.K., M.J.G.), Kobe, Center for iPS Cell Research and Application (CiRA) (A.W., Y.N., M.N., J.K., Y. Kitano, N.A., M.U., F.K., A.T., N.T., S.Y.), Institute for Integrated Cell-Material Sciences (iCeMS) (A.W.), and Department of Pathology and Tumor Biology, Graduate School of Medicine (K.Y., S. Ogawa), Kyoto University, Kyoto, the Department of Biostatistics, Hyogo College of Medicine, Nishinomiya (T.D.), Platform of Therapeutics for Rare Disease, National Institutes of Biomedical Innovation, Health, and Nutrition, Ibaraki (H.A.), Mitsubishi Space Software, Tokyo (S.T., Y.O., C.O.), the Department of Ophthalmology, Kawasaki Medical School, Kurashiki (H.K.), Japan Tissue Engineering, Gamagori (C.S., K.H.), and HEALIOS K.K., Tokyo (M.S.) — all in Japan; and Gladstone Institute of Cardiovascular Disease, San Francisco (S.Y.)
– sequence: 27
  givenname: Yasuo
  surname: Ohara
  fullname: Ohara, Yasuo
  organization: From the Division of Ophthalmology, Institute of Biomedical Research and Innovation Hospital, Foundation for Biomedical Research and Innovation (M.M., Y. Kurimoto, Y.H., M.F., M.Y., S. Ohta, M. Takahashi), Laboratory for Retinal Regeneration, RIKEN Center for Developmental Biology (M.M., C.M., H.A., N.S., Y.S., M. Terada, H.K., S.S., A.O., M.Y., M. Takahashi), the Department of Ophthalmology, Kobe City Medical Center General Hospital (Y.Kurimoto, Y.H., M.F.), the Department of Clinical Trial Management, Institute of Biomedical Research and Innovation Hospital, Foundation for Biomedical Research and Innovation (T.I., K.F.), and Research and Development Center for Cell Therapy, Foundation for Biomedical Research and Innovation (S.K., M.J.G.), Kobe, Center for iPS Cell Research and Application (CiRA) (A.W., Y.N., M.N., J.K., Y. Kitano, N.A., M.U., F.K., A.T., N.T., S.Y.), Institute for Integrated Cell-Material Sciences (iCeMS) (A.W.), and Department of Pathology and Tumor Biology, Graduate School of Medicine (K.Y., S. Ogawa), Kyoto University, Kyoto, the Department of Biostatistics, Hyogo College of Medicine, Nishinomiya (T.D.), Platform of Therapeutics for Rare Disease, National Institutes of Biomedical Innovation, Health, and Nutrition, Ibaraki (H.A.), Mitsubishi Space Software, Tokyo (S.T., Y.O., C.O.), the Department of Ophthalmology, Kawasaki Medical School, Kurashiki (H.K.), Japan Tissue Engineering, Gamagori (C.S., K.H.), and HEALIOS K.K., Tokyo (M.S.) — all in Japan; and Gladstone Institute of Cardiovascular Disease, San Francisco (S.Y.)
– sequence: 28
  givenname: Kenichi
  surname: Yoshida
  fullname: Yoshida, Kenichi
  organization: From the Division of Ophthalmology, Institute of Biomedical Research and Innovation Hospital, Foundation for Biomedical Research and Innovation (M.M., Y. Kurimoto, Y.H., M.F., M.Y., S. Ohta, M. Takahashi), Laboratory for Retinal Regeneration, RIKEN Center for Developmental Biology (M.M., C.M., H.A., N.S., Y.S., M. Terada, H.K., S.S., A.O., M.Y., M. Takahashi), the Department of Ophthalmology, Kobe City Medical Center General Hospital (Y.Kurimoto, Y.H., M.F.), the Department of Clinical Trial Management, Institute of Biomedical Research and Innovation Hospital, Foundation for Biomedical Research and Innovation (T.I., K.F.), and Research and Development Center for Cell Therapy, Foundation for Biomedical Research and Innovation (S.K., M.J.G.), Kobe, Center for iPS Cell Research and Application (CiRA) (A.W., Y.N., M.N., J.K., Y. Kitano, N.A., M.U., F.K., A.T., N.T., S.Y.), Institute for Integrated Cell-Material Sciences (iCeMS) (A.W.), and Department of Pathology and Tumor Biology, Graduate School of Medicine (K.Y., S. Ogawa), Kyoto University, Kyoto, the Department of Biostatistics, Hyogo College of Medicine, Nishinomiya (T.D.), Platform of Therapeutics for Rare Disease, National Institutes of Biomedical Innovation, Health, and Nutrition, Ibaraki (H.A.), Mitsubishi Space Software, Tokyo (S.T., Y.O., C.O.), the Department of Ophthalmology, Kawasaki Medical School, Kurashiki (H.K.), Japan Tissue Engineering, Gamagori (C.S., K.H.), and HEALIOS K.K., Tokyo (M.S.) — all in Japan; and Gladstone Institute of Cardiovascular Disease, San Francisco (S.Y.)
– sequence: 29
  givenname: Junko
  surname: Kuwahara
  fullname: Kuwahara, Junko
  organization: From the Division of Ophthalmology, Institute of Biomedical Research and Innovation Hospital, Foundation for Biomedical Research and Innovation (M.M., Y. Kurimoto, Y.H., M.F., M.Y., S. Ohta, M. Takahashi), Laboratory for Retinal Regeneration, RIKEN Center for Developmental Biology (M.M., C.M., H.A., N.S., Y.S., M. Terada, H.K., S.S., A.O., M.Y., M. Takahashi), the Department of Ophthalmology, Kobe City Medical Center General Hospital (Y.Kurimoto, Y.H., M.F.), the Department of Clinical Trial Management, Institute of Biomedical Research and Innovation Hospital, Foundation for Biomedical Research and Innovation (T.I., K.F.), and Research and Development Center for Cell Therapy, Foundation for Biomedical Research and Innovation (S.K., M.J.G.), Kobe, Center for iPS Cell Research and Application (CiRA) (A.W., Y.N., M.N., J.K., Y. Kitano, N.A., M.U., F.K., A.T., N.T., S.Y.), Institute for Integrated Cell-Material Sciences (iCeMS) (A.W.), and Department of Pathology and Tumor Biology, Graduate School of Medicine (K.Y., S. Ogawa), Kyoto University, Kyoto, the Department of Biostatistics, Hyogo College of Medicine, Nishinomiya (T.D.), Platform of Therapeutics for Rare Disease, National Institutes of Biomedical Innovation, Health, and Nutrition, Ibaraki (H.A.), Mitsubishi Space Software, Tokyo (S.T., Y.O., C.O.), the Department of Ophthalmology, Kawasaki Medical School, Kurashiki (H.K.), Japan Tissue Engineering, Gamagori (C.S., K.H.), and HEALIOS K.K., Tokyo (M.S.) — all in Japan; and Gladstone Institute of Cardiovascular Disease, San Francisco (S.Y.)
– sequence: 30
  givenname: Yuko
  surname: Kitano
  fullname: Kitano, Yuko
  organization: From the Division of Ophthalmology, Institute of Biomedical Research and Innovation Hospital, Foundation for Biomedical Research and Innovation (M.M., Y. Kurimoto, Y.H., M.F., M.Y., S. Ohta, M. Takahashi), Laboratory for Retinal Regeneration, RIKEN Center for Developmental Biology (M.M., C.M., H.A., N.S., Y.S., M. Terada, H.K., S.S., A.O., M.Y., M. Takahashi), the Department of Ophthalmology, Kobe City Medical Center General Hospital (Y.Kurimoto, Y.H., M.F.), the Department of Clinical Trial Management, Institute of Biomedical Research and Innovation Hospital, Foundation for Biomedical Research and Innovation (T.I., K.F.), and Research and Development Center for Cell Therapy, Foundation for Biomedical Research and Innovation (S.K., M.J.G.), Kobe, Center for iPS Cell Research and Application (CiRA) (A.W., Y.N., M.N., J.K., Y. Kitano, N.A., M.U., F.K., A.T., N.T., S.Y.), Institute for Integrated Cell-Material Sciences (iCeMS) (A.W.), and Department of Pathology and Tumor Biology, Graduate School of Medicine (K.Y., S. Ogawa), Kyoto University, Kyoto, the Department of Biostatistics, Hyogo College of Medicine, Nishinomiya (T.D.), Platform of Therapeutics for Rare Disease, National Institutes of Biomedical Innovation, Health, and Nutrition, Ibaraki (H.A.), Mitsubishi Space Software, Tokyo (S.T., Y.O., C.O.), the Department of Ophthalmology, Kawasaki Medical School, Kurashiki (H.K.), Japan Tissue Engineering, Gamagori (C.S., K.H.), and HEALIOS K.K., Tokyo (M.S.) — all in Japan; and Gladstone Institute of Cardiovascular Disease, San Francisco (S.Y.)
– sequence: 31
  givenname: Naoki
  surname: Amano
  fullname: Amano, Naoki
  organization: From the Division of Ophthalmology, Institute of Biomedical Research and Innovation Hospital, Foundation for Biomedical Research and Innovation (M.M., Y. Kurimoto, Y.H., M.F., M.Y., S. Ohta, M. Takahashi), Laboratory for Retinal Regeneration, RIKEN Center for Developmental Biology (M.M., C.M., H.A., N.S., Y.S., M. Terada, H.K., S.S., A.O., M.Y., M. Takahashi), the Department of Ophthalmology, Kobe City Medical Center General Hospital (Y.Kurimoto, Y.H., M.F.), the Department of Clinical Trial Management, Institute of Biomedical Research and Innovation Hospital, Foundation for Biomedical Research and Innovation (T.I., K.F.), and Research and Development Center for Cell Therapy, Foundation for Biomedical Research and Innovation (S.K., M.J.G.), Kobe, Center for iPS Cell Research and Application (CiRA) (A.W., Y.N., M.N., J.K., Y. Kitano, N.A., M.U., F.K., A.T., N.T., S.Y.), Institute for Integrated Cell-Material Sciences (iCeMS) (A.W.), and Department of Pathology and Tumor Biology, Graduate School of Medicine (K.Y., S. Ogawa), Kyoto University, Kyoto, the Department of Biostatistics, Hyogo College of Medicine, Nishinomiya (T.D.), Platform of Therapeutics for Rare Disease, National Institutes of Biomedical Innovation, Health, and Nutrition, Ibaraki (H.A.), Mitsubishi Space Software, Tokyo (S.T., Y.O., C.O.), the Department of Ophthalmology, Kawasaki Medical School, Kurashiki (H.K.), Japan Tissue Engineering, Gamagori (C.S., K.H.), and HEALIOS K.K., Tokyo (M.S.) — all in Japan; and Gladstone Institute of Cardiovascular Disease, San Francisco (S.Y.)
– sequence: 32
  givenname: Masafumi
  surname: Umekage
  fullname: Umekage, Masafumi
  organization: From the Division of Ophthalmology, Institute of Biomedical Research and Innovation Hospital, Foundation for Biomedical Research and Innovation (M.M., Y. Kurimoto, Y.H., M.F., M.Y., S. Ohta, M. Takahashi), Laboratory for Retinal Regeneration, RIKEN Center for Developmental Biology (M.M., C.M., H.A., N.S., Y.S., M. Terada, H.K., S.S., A.O., M.Y., M. Takahashi), the Department of Ophthalmology, Kobe City Medical Center General Hospital (Y.Kurimoto, Y.H., M.F.), the Department of Clinical Trial Management, Institute of Biomedical Research and Innovation Hospital, Foundation for Biomedical Research and Innovation (T.I., K.F.), and Research and Development Center for Cell Therapy, Foundation for Biomedical Research and Innovation (S.K., M.J.G.), Kobe, Center for iPS Cell Research and Application (CiRA) (A.W., Y.N., M.N., J.K., Y. Kitano, N.A., M.U., F.K., A.T., N.T., S.Y.), Institute for Integrated Cell-Material Sciences (iCeMS) (A.W.), and Department of Pathology and Tumor Biology, Graduate School of Medicine (K.Y., S. Ogawa), Kyoto University, Kyoto, the Department of Biostatistics, Hyogo College of Medicine, Nishinomiya (T.D.), Platform of Therapeutics for Rare Disease, National Institutes of Biomedical Innovation, Health, and Nutrition, Ibaraki (H.A.), Mitsubishi Space Software, Tokyo (S.T., Y.O., C.O.), the Department of Ophthalmology, Kawasaki Medical School, Kurashiki (H.K.), Japan Tissue Engineering, Gamagori (C.S., K.H.), and HEALIOS K.K., Tokyo (M.S.) — all in Japan; and Gladstone Institute of Cardiovascular Disease, San Francisco (S.Y.)
– sequence: 33
  givenname: Fumiyo
  surname: Kitaoka
  fullname: Kitaoka, Fumiyo
  organization: From the Division of Ophthalmology, Institute of Biomedical Research and Innovation Hospital, Foundation for Biomedical Research and Innovation (M.M., Y. Kurimoto, Y.H., M.F., M.Y., S. Ohta, M. Takahashi), Laboratory for Retinal Regeneration, RIKEN Center for Developmental Biology (M.M., C.M., H.A., N.S., Y.S., M. Terada, H.K., S.S., A.O., M.Y., M. Takahashi), the Department of Ophthalmology, Kobe City Medical Center General Hospital (Y.Kurimoto, Y.H., M.F.), the Department of Clinical Trial Management, Institute of Biomedical Research and Innovation Hospital, Foundation for Biomedical Research and Innovation (T.I., K.F.), and Research and Development Center for Cell Therapy, Foundation for Biomedical Research and Innovation (S.K., M.J.G.), Kobe, Center for iPS Cell Research and Application (CiRA) (A.W., Y.N., M.N., J.K., Y. Kitano, N.A., M.U., F.K., A.T., N.T., S.Y.), Institute for Integrated Cell-Material Sciences (iCeMS) (A.W.), and Department of Pathology and Tumor Biology, Graduate School of Medicine (K.Y., S. Ogawa), Kyoto University, Kyoto, the Department of Biostatistics, Hyogo College of Medicine, Nishinomiya (T.D.), Platform of Therapeutics for Rare Disease, National Institutes of Biomedical Innovation, Health, and Nutrition, Ibaraki (H.A.), Mitsubishi Space Software, Tokyo (S.T., Y.O., C.O.), the Department of Ophthalmology, Kawasaki Medical School, Kurashiki (H.K.), Japan Tissue Engineering, Gamagori (C.S., K.H.), and HEALIOS K.K., Tokyo (M.S.) — all in Japan; and Gladstone Institute of Cardiovascular Disease, San Francisco (S.Y.)
– sequence: 34
  givenname: Azusa
  surname: Tanaka
  fullname: Tanaka, Azusa
  organization: From the Division of Ophthalmology, Institute of Biomedical Research and Innovation Hospital, Foundation for Biomedical Research and Innovation (M.M., Y. Kurimoto, Y.H., M.F., M.Y., S. Ohta, M. Takahashi), Laboratory for Retinal Regeneration, RIKEN Center for Developmental Biology (M.M., C.M., H.A., N.S., Y.S., M. Terada, H.K., S.S., A.O., M.Y., M. Takahashi), the Department of Ophthalmology, Kobe City Medical Center General Hospital (Y.Kurimoto, Y.H., M.F.), the Department of Clinical Trial Management, Institute of Biomedical Research and Innovation Hospital, Foundation for Biomedical Research and Innovation (T.I., K.F.), and Research and Development Center for Cell Therapy, Foundation for Biomedical Research and Innovation (S.K., M.J.G.), Kobe, Center for iPS Cell Research and Application (CiRA) (A.W., Y.N., M.N., J.K., Y. Kitano, N.A., M.U., F.K., A.T., N.T., S.Y.), Institute for Integrated Cell-Material Sciences (iCeMS) (A.W.), and Department of Pathology and Tumor Biology, Graduate School of Medicine (K.Y., S. Ogawa), Kyoto University, Kyoto, the Department of Biostatistics, Hyogo College of Medicine, Nishinomiya (T.D.), Platform of Therapeutics for Rare Disease, National Institutes of Biomedical Innovation, Health, and Nutrition, Ibaraki (H.A.), Mitsubishi Space Software, Tokyo (S.T., Y.O., C.O.), the Department of Ophthalmology, Kawasaki Medical School, Kurashiki (H.K.), Japan Tissue Engineering, Gamagori (C.S., K.H.), and HEALIOS K.K., Tokyo (M.S.) — all in Japan; and Gladstone Institute of Cardiovascular Disease, San Francisco (S.Y.)
– sequence: 35
  givenname: Chihiro
  surname: Okada
  fullname: Okada, Chihiro
  organization: From the Division of Ophthalmology, Institute of Biomedical Research and Innovation Hospital, Foundation for Biomedical Research and Innovation (M.M., Y. Kurimoto, Y.H., M.F., M.Y., S. Ohta, M. Takahashi), Laboratory for Retinal Regeneration, RIKEN Center for Developmental Biology (M.M., C.M., H.A., N.S., Y.S., M. Terada, H.K., S.S., A.O., M.Y., M. Takahashi), the Department of Ophthalmology, Kobe City Medical Center General Hospital (Y.Kurimoto, Y.H., M.F.), the Department of Clinical Trial Management, Institute of Biomedical Research and Innovation Hospital, Foundation for Biomedical Research and Innovation (T.I., K.F.), and Research and Development Center for Cell Therapy, Foundation for Biomedical Research and Innovation (S.K., M.J.G.), Kobe, Center for iPS Cell Research and Application (CiRA) (A.W., Y.N., M.N., J.K., Y. Kitano, N.A., M.U., F.K., A.T., N.T., S.Y.), Institute for Integrated Cell-Material Sciences (iCeMS) (A.W.), and Department of Pathology and Tumor Biology, Graduate School of Medicine (K.Y., S. Ogawa), Kyoto University, Kyoto, the Department of Biostatistics, Hyogo College of Medicine, Nishinomiya (T.D.), Platform of Therapeutics for Rare Disease, National Institutes of Biomedical Innovation, Health, and Nutrition, Ibaraki (H.A.), Mitsubishi Space Software, Tokyo (S.T., Y.O., C.O.), the Department of Ophthalmology, Kawasaki Medical School, Kurashiki (H.K.), Japan Tissue Engineering, Gamagori (C.S., K.H.), and HEALIOS K.K., Tokyo (M.S.) — all in Japan; and Gladstone Institute of Cardiovascular Disease, San Francisco (S.Y.)
– sequence: 36
  givenname: Naoko
  surname: Takasu
  fullname: Takasu, Naoko
  organization: From the Division of Ophthalmology, Institute of Biomedical Research and Innovation Hospital, Foundation for Biomedical Research and Innovation (M.M., Y. Kurimoto, Y.H., M.F., M.Y., S. Ohta, M. Takahashi), Laboratory for Retinal Regeneration, RIKEN Center for Developmental Biology (M.M., C.M., H.A., N.S., Y.S., M. Terada, H.K., S.S., A.O., M.Y., M. Takahashi), the Department of Ophthalmology, Kobe City Medical Center General Hospital (Y.Kurimoto, Y.H., M.F.), the Department of Clinical Trial Management, Institute of Biomedical Research and Innovation Hospital, Foundation for Biomedical Research and Innovation (T.I., K.F.), and Research and Development Center for Cell Therapy, Foundation for Biomedical Research and Innovation (S.K., M.J.G.), Kobe, Center for iPS Cell Research and Application (CiRA) (A.W., Y.N., M.N., J.K., Y. Kitano, N.A., M.U., F.K., A.T., N.T., S.Y.), Institute for Integrated Cell-Material Sciences (iCeMS) (A.W.), and Department of Pathology and Tumor Biology, Graduate School of Medicine (K.Y., S. Ogawa), Kyoto University, Kyoto, the Department of Biostatistics, Hyogo College of Medicine, Nishinomiya (T.D.), Platform of Therapeutics for Rare Disease, National Institutes of Biomedical Innovation, Health, and Nutrition, Ibaraki (H.A.), Mitsubishi Space Software, Tokyo (S.T., Y.O., C.O.), the Department of Ophthalmology, Kawasaki Medical School, Kurashiki (H.K.), Japan Tissue Engineering, Gamagori (C.S., K.H.), and HEALIOS K.K., Tokyo (M.S.) — all in Japan; and Gladstone Institute of Cardiovascular Disease, San Francisco (S.Y.)
– sequence: 37
  givenname: Seishi
  surname: Ogawa
  fullname: Ogawa, Seishi
  organization: From the Division of Ophthalmology, Institute of Biomedical Research and Innovation Hospital, Foundation for Biomedical Research and Innovation (M.M., Y. Kurimoto, Y.H., M.F., M.Y., S. Ohta, M. Takahashi), Laboratory for Retinal Regeneration, RIKEN Center for Developmental Biology (M.M., C.M., H.A., N.S., Y.S., M. Terada, H.K., S.S., A.O., M.Y., M. Takahashi), the Department of Ophthalmology, Kobe City Medical Center General Hospital (Y.Kurimoto, Y.H., M.F.), the Department of Clinical Trial Management, Institute of Biomedical Research and Innovation Hospital, Foundation for Biomedical Research and Innovation (T.I., K.F.), and Research and Development Center for Cell Therapy, Foundation for Biomedical Research and Innovation (S.K., M.J.G.), Kobe, Center for iPS Cell Research and Application (CiRA) (A.W., Y.N., M.N., J.K., Y. Kitano, N.A., M.U., F.K., A.T., N.T., S.Y.), Institute for Integrated Cell-Material Sciences (iCeMS) (A.W.), and Department of Pathology and Tumor Biology, Graduate School of Medicine (K.Y., S. Ogawa), Kyoto University, Kyoto, the Department of Biostatistics, Hyogo College of Medicine, Nishinomiya (T.D.), Platform of Therapeutics for Rare Disease, National Institutes of Biomedical Innovation, Health, and Nutrition, Ibaraki (H.A.), Mitsubishi Space Software, Tokyo (S.T., Y.O., C.O.), the Department of Ophthalmology, Kawasaki Medical School, Kurashiki (H.K.), Japan Tissue Engineering, Gamagori (C.S., K.H.), and HEALIOS K.K., Tokyo (M.S.) — all in Japan; and Gladstone Institute of Cardiovascular Disease, San Francisco (S.Y.)
– sequence: 38
  givenname: Shinya
  surname: Yamanaka
  fullname: Yamanaka, Shinya
  organization: From the Division of Ophthalmology, Institute of Biomedical Research and Innovation Hospital, Foundation for Biomedical Research and Innovation (M.M., Y. Kurimoto, Y.H., M.F., M.Y., S. Ohta, M. Takahashi), Laboratory for Retinal Regeneration, RIKEN Center for Developmental Biology (M.M., C.M., H.A., N.S., Y.S., M. Terada, H.K., S.S., A.O., M.Y., M. Takahashi), the Department of Ophthalmology, Kobe City Medical Center General Hospital (Y.Kurimoto, Y.H., M.F.), the Department of Clinical Trial Management, Institute of Biomedical Research and Innovation Hospital, Foundation for Biomedical Research and Innovation (T.I., K.F.), and Research and Development Center for Cell Therapy, Foundation for Biomedical Research and Innovation (S.K., M.J.G.), Kobe, Center for iPS Cell Research and Application (CiRA) (A.W., Y.N., M.N., J.K., Y. Kitano, N.A., M.U., F.K., A.T., N.T., S.Y.), Institute for Integrated Cell-Material Sciences (iCeMS) (A.W.), and Department of Pathology and Tumor Biology, Graduate School of Medicine (K.Y., S. Ogawa), Kyoto University, Kyoto, the Department of Biostatistics, Hyogo College of Medicine, Nishinomiya (T.D.), Platform of Therapeutics for Rare Disease, National Institutes of Biomedical Innovation, Health, and Nutrition, Ibaraki (H.A.), Mitsubishi Space Software, Tokyo (S.T., Y.O., C.O.), the Department of Ophthalmology, Kawasaki Medical School, Kurashiki (H.K.), Japan Tissue Engineering, Gamagori (C.S., K.H.), and HEALIOS K.K., Tokyo (M.S.) — all in Japan; and Gladstone Institute of Cardiovascular Disease, San Francisco (S.Y.)
– sequence: 39
  givenname: Masayo
  surname: Takahashi
  fullname: Takahashi, Masayo
  organization: From the Division of Ophthalmology, Institute of Biomedical Research and Innovation Hospital, Foundation for Biomedical Research and Innovation (M.M., Y. Kurimoto, Y.H., M.F., M.Y., S. Ohta, M. Takahashi), Laboratory for Retinal Regeneration, RIKEN Center for Developmental Biology (M.M., C.M., H.A., N.S., Y.S., M. Terada, H.K., S.S., A.O., M.Y., M. Takahashi), the Department of Ophthalmology, Kobe City Medical Center General Hospital (Y.Kurimoto, Y.H., M.F.), the Department of Clinical Trial Management, Institute of Biomedical Research and Innovation Hospital, Foundation for Biomedical Research and Innovation (T.I., K.F.), and Research and Development Center for Cell Therapy, Foundation for Biomedical Research and Innovation (S.K., M.J.G.), Kobe, Center for iPS Cell Research and Application (CiRA) (A.W., Y.N., M.N., J.K., Y. Kitano, N.A., M.U., F.K., A.T., N.T., S.Y.), Institute for Integrated Cell-Material Sciences (iCeMS) (A.W.), and Department of Pathology and Tumor Biology, Graduate School of Medicine (K.Y., S. Ogawa), Kyoto University, Kyoto, the Department of Biostatistics, Hyogo College of Medicine, Nishinomiya (T.D.), Platform of Therapeutics for Rare Disease, National Institutes of Biomedical Innovation, Health, and Nutrition, Ibaraki (H.A.), Mitsubishi Space Software, Tokyo (S.T., Y.O., C.O.), the Department of Ophthalmology, Kawasaki Medical School, Kurashiki (H.K.), Japan Tissue Engineering, Gamagori (C.S., K.H.), and HEALIOS K.K., Tokyo (M.S.) — all in Japan; and Gladstone Institute of Cardiovascular Disease, San Francisco (S.Y.)
BackLink https://www.ncbi.nlm.nih.gov/pubmed/28296613$$D View this record in MEDLINE/PubMed
BookMark eNp10VtLwzAUAOAgirvoo69SEMGXatI0afIo29TJpuDluWTp6ehom5m0gm_-B_-hv8TMTUFheTlw-E44lx7arU0NCB0RfE4w4xd3o9upUYRjQbnYQV3CKA3jGPNd1MU4EmGcSNpBPecW2D8Sy33UiUQkOSe0i6aXbWNKMzetC8Z11mrIgscGqnAAZfn5_jEEW7z63AM0Ra3KYJV2QW5sMFW6LZUNhjCHGqxqClMfoL1clQ4ON7GPnq9GT4ObcHJ_PR5cTkIdM96EGWFczDLGdJLMuNaECRbLnDEldZYrSJjkLIsj32QkSaKxiEVGQSYCKCec0T46W_-7tOalBdekVeG0b03V4CdJiUgESfyIwtOTf3RhWutHWSlJhOBCRF4db1Q7qyBLl7aolH1LfxblQbgG2hrnLOS_hOB0dYj0zyG8p_-8LprvHTVWFeXWqtN1VVW5tIZFtcV9Ae5blYg
CitedBy_id crossref_primary_10_1038_s41598_022_10540_1
crossref_primary_10_1007_s12015_022_10387_z
crossref_primary_10_3389_fbioe_2020_00455
crossref_primary_10_1093_stcltm_szac014
crossref_primary_10_1155_2019_6927829
crossref_primary_10_1038_s41598_023_37235_5
crossref_primary_10_1038_s41598_018_35506_0
crossref_primary_10_1155_2019_8203950
crossref_primary_10_1016_j_bioactmat_2022_10_022
crossref_primary_10_1038_s41598_021_00703_x
crossref_primary_10_1016_j_stemcr_2020_12_007
crossref_primary_10_1089_scd_2018_0084
crossref_primary_10_1093_stmcls_sxac020
crossref_primary_10_1016_j_scr_2021_102283
crossref_primary_10_1016_j_stemcr_2017_05_029
crossref_primary_10_1016_j_mtbio_2022_100253
crossref_primary_10_1016_j_arr_2018_05_006
crossref_primary_10_3389_fimmu_2019_02809
crossref_primary_10_1016_j_cobme_2022_100390
crossref_primary_10_1002_sctm_18_0134
crossref_primary_10_1002_adma_202406333
crossref_primary_10_1016_j_stemcr_2023_10_008
crossref_primary_10_1038_s41598_017_15212_z
crossref_primary_10_1186_s12929_019_0578_x
crossref_primary_10_1523_JNEUROSCI_0518_19_2019
crossref_primary_10_1089_scd_2018_0076
crossref_primary_10_1177_09636897241228026
crossref_primary_10_1126_scitranslmed_aat5580
crossref_primary_10_1038_s41598_020_64601_4
crossref_primary_10_1016_j_mcn_2020_103523
crossref_primary_10_1080_01677063_2017_1395876
crossref_primary_10_3390_jpm12091485
crossref_primary_10_1371_journal_pgen_1007939
crossref_primary_10_1038_s41576_019_0100_z
crossref_primary_10_1016_j_gendis_2020_11_020
crossref_primary_10_1093_stcltm_szac001
crossref_primary_10_1016_j_survophthal_2024_08_002
crossref_primary_10_1016_j_stemcr_2020_05_005
crossref_primary_10_1093_stmcls_sxac040
crossref_primary_10_1016_j_stem_2023_11_004
crossref_primary_10_1089_cell_2019_0070
crossref_primary_10_1089_ten_teb_2018_0124
crossref_primary_10_4103_1673_5374_332123
crossref_primary_10_2174_1570159X22666240603084558
crossref_primary_10_1007_s11892_017_0901_4
crossref_primary_10_1038_s41421_018_0053_y
crossref_primary_10_1093_icvts_ivy208
crossref_primary_10_1186_s40824_018_0148_4
crossref_primary_10_1186_s40942_019_0194_7
crossref_primary_10_1007_s12268_018_0984_8
crossref_primary_10_3390_cells8121536
crossref_primary_10_1038_s41551_021_00836_4
crossref_primary_10_1080_02713683_2020_1722180
crossref_primary_10_1007_s40135_018_0160_9
crossref_primary_10_1038_s41419_020_02955_3
crossref_primary_10_1038_pr_2017_244
crossref_primary_10_1097_IAE_0000000000003655
crossref_primary_10_1242_jcs_260753
crossref_primary_10_3390_biomedicines11123221
crossref_primary_10_1038_s41536_021_00183_7
crossref_primary_10_1210_endocr_bqac004
crossref_primary_10_3390_jcm10081785
crossref_primary_10_1038_s41598_020_70707_6
crossref_primary_10_1161_CIRCRESAHA_119_315209
crossref_primary_10_3390_cells13110893
crossref_primary_10_3390_jcm8030288
crossref_primary_10_3389_fbioe_2019_00373
crossref_primary_10_1038_pr_2017_232
crossref_primary_10_1080_21678707_2018_1549480
crossref_primary_10_3390_ijms20225759
crossref_primary_10_1002_eer3_4
crossref_primary_10_3389_fsurg_2021_731031
crossref_primary_10_1002_stem_2865
crossref_primary_10_3390_cells9112497
crossref_primary_10_1161_CIRCHEARTFAILURE_118_005425
crossref_primary_10_1186_s13287_022_02931_y
crossref_primary_10_1038_s41598_020_73908_1
crossref_primary_10_1146_annurev_pharmtox_010919_023245
crossref_primary_10_1177_15353702221114099
crossref_primary_10_1016_j_stemcr_2019_08_014
crossref_primary_10_1089_jop_2024_0130
crossref_primary_10_1051_medsci_2019155
crossref_primary_10_1016_j_yexcr_2019_01_025
crossref_primary_10_1242_dev_192567
crossref_primary_10_3390_jpm11090905
crossref_primary_10_1038_pr_2017_229
crossref_primary_10_1093_hropen_hoy024
crossref_primary_10_1167_iovs_18_24769
crossref_primary_10_1186_s12929_020_00682_7
crossref_primary_10_3390_cells9020483
crossref_primary_10_1080_14712598_2024_2443079
crossref_primary_10_3389_fnins_2022_938089
crossref_primary_10_1097_ICU_0000000000001034
crossref_primary_10_1002_sctm_19_0396
crossref_primary_10_1186_s12967_024_05016_x
crossref_primary_10_1016_j_gendis_2017_03_001
crossref_primary_10_1186_s13287_022_02879_z
crossref_primary_10_3390_app11052154
crossref_primary_10_1089_wound_2021_0049
crossref_primary_10_3390_cells8070703
crossref_primary_10_1038_s41434_019_0058_7
crossref_primary_10_17116_oftalma2019135052226
crossref_primary_10_3389_fmed_2021_756029
crossref_primary_10_1089_scd_2017_0059
crossref_primary_10_1007_s12015_020_09990_9
crossref_primary_10_4103_singaporemedj_SMJ_2022_179
crossref_primary_10_1016_j_jjcc_2020_03_013
crossref_primary_10_1177_2515841418774433
crossref_primary_10_1186_s13287_024_04118_z
crossref_primary_10_1111_1751_2980_13072
crossref_primary_10_1007_s00417_023_06014_3
crossref_primary_10_1084_jem_20230913
crossref_primary_10_1089_scd_2017_0090
crossref_primary_10_1080_02713683_2019_1681004
crossref_primary_10_3390_biomedicines11020310
crossref_primary_10_54097_hset_v66i_11707
crossref_primary_10_1016_j_reth_2023_09_008
crossref_primary_10_3233_JPD_230328
crossref_primary_10_1007_s40778_018_0145_5
crossref_primary_10_2217_rme_2017_0089
crossref_primary_10_3390_bioengineering7020036
crossref_primary_10_1016_j_tibtech_2020_10_012
crossref_primary_10_1038_s41467_017_01631_z
crossref_primary_10_1089_scd_2020_0084
crossref_primary_10_1016_j_stemcr_2020_06_014
crossref_primary_10_1242_jcs_232223
crossref_primary_10_3390_ijms23158722
crossref_primary_10_3892_ol_2019_10549
crossref_primary_10_1007_s12015_020_10029_2
crossref_primary_10_1016_j_healun_2024_04_003
crossref_primary_10_3389_fcell_2020_588050
crossref_primary_10_1016_j_xops_2025_100770
crossref_primary_10_1172_JCI125015
crossref_primary_10_5500_wjt_v14_i4_97690
crossref_primary_10_1007_s10792_023_02767_2
crossref_primary_10_1007_s40610_017_0069_3
crossref_primary_10_1186_s13229_021_00417_x
crossref_primary_10_1007_s12015_024_10740_4
crossref_primary_10_3390_ijms222111317
crossref_primary_10_2217_rme_2017_0077
crossref_primary_10_1007_s40135_022_00287_3
crossref_primary_10_18632_aging_203496
crossref_primary_10_3389_fcell_2021_741368
crossref_primary_10_1016_j_preteyeres_2018_11_003
crossref_primary_10_17816_gc622899
crossref_primary_10_1016_j_preteyeres_2018_03_003
crossref_primary_10_1021_acs_biomac_0c00293
crossref_primary_10_1038_s41598_022_11192_x
crossref_primary_10_3390_ijms19082366
crossref_primary_10_4103_1673_5374_300329
crossref_primary_10_1016_j_preteyeres_2018_03_001
crossref_primary_10_1186_s13287_021_02395_6
crossref_primary_10_1016_j_stemcr_2023_01_007
crossref_primary_10_1016_j_preteyeres_2018_11_001
crossref_primary_10_1007_s11427_019_1684_x
crossref_primary_10_1089_cell_2018_0024
crossref_primary_10_3389_fcell_2023_1188905
crossref_primary_10_1016_j_biomaterials_2019_119603
crossref_primary_10_1186_s13287_024_04007_5
crossref_primary_10_1038_s41598_018_21651_z
crossref_primary_10_1007_s00109_020_01960_5
crossref_primary_10_1088_1361_6420_ad617d
crossref_primary_10_3390_cells10030568
crossref_primary_10_1038_s41536_019_0081_8
crossref_primary_10_4236_ojots_2018_82002
crossref_primary_10_3390_mi14111998
crossref_primary_10_1098_rstb_2017_0213
crossref_primary_10_1167_tvst_11_4_24
crossref_primary_10_3390_medicina57010064
crossref_primary_10_1016_j_pmatsci_2019_02_002
crossref_primary_10_1098_rstb_2017_0219
crossref_primary_10_1038_s41467_023_40901_x
crossref_primary_10_1016_j_biomaterials_2024_122770
crossref_primary_10_1186_s13287_022_02720_7
crossref_primary_10_1016_j_oret_2022_04_009
crossref_primary_10_1016_j_isci_2022_104729
crossref_primary_10_1038_s41573_020_0064_x
crossref_primary_10_1016_j_copbio_2017_12_014
crossref_primary_10_1007_s43032_021_00503_8
crossref_primary_10_3390_ijms222212298
crossref_primary_10_1038_ncb3652
crossref_primary_10_1111_aos_14004
crossref_primary_10_4252_wjsc_v13_i5_366
crossref_primary_10_1007_s11892_019_1167_9
crossref_primary_10_1038_s41392_022_01251_0
crossref_primary_10_1038_s41585_019_0246_7
crossref_primary_10_1093_stcltm_szac060
crossref_primary_10_1016_j_stemcr_2023_03_005
crossref_primary_10_1016_S1773_035X_18_30355_1
crossref_primary_10_3390_diagnostics14101005
crossref_primary_10_4103_IJO_IJO_2806_22
crossref_primary_10_1186_s13287_023_03308_5
crossref_primary_10_7759_cureus_67067
crossref_primary_10_1016_j_addr_2023_114870
crossref_primary_10_2174_1876893801805010031
crossref_primary_10_1097_WNO_0000000000001375
crossref_primary_10_1016_j_reth_2021_12_007
crossref_primary_10_1098_rsob_190010
crossref_primary_10_3390_ijms21197279
crossref_primary_10_1007_s40291_018_0332_1
crossref_primary_10_1080_02713683_2022_2079144
crossref_primary_10_1515_jpm_2022_0510
crossref_primary_10_7554_eLife_77007
crossref_primary_10_4103_1673_5374_335826
crossref_primary_10_1016_j_psychres_2024_116033
crossref_primary_10_1016_j_colcom_2023_100734
crossref_primary_10_1186_s41232_023_00307_0
crossref_primary_10_1371_journal_pone_0236600
crossref_primary_10_1093_stcltm_szac036
crossref_primary_10_15421_10_15421_022366
crossref_primary_10_1089_ten_tea_2019_0118
crossref_primary_10_1016_j_clinthera_2018_10_001
crossref_primary_10_1093_stcltm_szac029
crossref_primary_10_1080_07853890_2022_2066169
crossref_primary_10_1155_2017_3250624
crossref_primary_10_1371_journal_pone_0223775
crossref_primary_10_1146_annurev_med_081117_010451
crossref_primary_10_1186_s13287_019_1402_y
crossref_primary_10_1016_S0001_4079_19_30420_0
crossref_primary_10_3390_ijms21197028
crossref_primary_10_1039_C7TB01152K
crossref_primary_10_1016_j_biotechadv_2019_107455
crossref_primary_10_1093_eurheartj_ehy388
crossref_primary_10_3390_ijms222111542
crossref_primary_10_1016_j_bioactmat_2023_08_003
crossref_primary_10_3389_fcell_2021_696434
crossref_primary_10_1007_s00059_017_4662_2
crossref_primary_10_1016_j_drudis_2017_07_012
crossref_primary_10_1002_bem_22394
crossref_primary_10_3389_fped_2022_855260
crossref_primary_10_3390_brainsci12121620
crossref_primary_10_3389_fceng_2022_1031395
crossref_primary_10_1186_s13287_023_03526_x
crossref_primary_10_1007_s12015_021_10262_3
crossref_primary_10_1002_wsbm_1515
crossref_primary_10_1016_j_ymthe_2021_01_001
crossref_primary_10_1016_j_celrep_2019_03_046
crossref_primary_10_1016_j_preteyeres_2024_101286
crossref_primary_10_1186_s13287_020_01608_8
crossref_primary_10_1038_s41598_018_38065_6
crossref_primary_10_1016_j_preteyeres_2024_101289
crossref_primary_10_59675_M2022_03
crossref_primary_10_1177_0963689717735411
crossref_primary_10_3390_app11094102
crossref_primary_10_1016_j_jmb_2020_01_024
crossref_primary_10_1038_s41583_019_0257_7
crossref_primary_10_1016_j_molmed_2020_04_005
crossref_primary_10_1186_s40942_019_0158_y
crossref_primary_10_1155_2019_4568979
crossref_primary_10_3390_ijms221910594
crossref_primary_10_1002_adhm_202301067
crossref_primary_10_1016_j_molmed_2018_06_006
crossref_primary_10_1042_ETLS20200151
crossref_primary_10_1007_s12015_020_09956_x
crossref_primary_10_1146_annurev_vision_120222_012817
crossref_primary_10_1080_14712598_2018_1473370
crossref_primary_10_18502_jovr_v17i4_12325
crossref_primary_10_1002_cne_24819
crossref_primary_10_6002_ect_MESOT2018_P99
crossref_primary_10_1016_j_arabjc_2023_104578
crossref_primary_10_1172_JCI133821
crossref_primary_10_23868_201707021
crossref_primary_10_1016_j_stemcr_2017_08_025
crossref_primary_10_1177_10738584221110100
crossref_primary_10_1126_science_aau1810
crossref_primary_10_1155_2018_1676851
crossref_primary_10_3390_ijms22169047
crossref_primary_10_1016_j_jcot_2018_04_009
crossref_primary_10_1186_s13287_021_02546_9
crossref_primary_10_1016_j_stemcr_2021_03_028
crossref_primary_10_1146_annurev_pathmechdis_012418_013046
crossref_primary_10_1056_NEJMe1701379
crossref_primary_10_3390_biomedicines10123269
crossref_primary_10_1002_biot_201800195
crossref_primary_10_1016_j_stem_2017_11_017
crossref_primary_10_1016_j_reth_2021_08_005
crossref_primary_10_1167_iovs_65_4_32
crossref_primary_10_1016_j_heliyon_2020_e04423
crossref_primary_10_1002_jnr_70027
crossref_primary_10_1038_s43856_024_00617_5
crossref_primary_10_1016_j_stemcr_2021_02_021
crossref_primary_10_3389_fnins_2018_00651
crossref_primary_10_3390_ijms24032476
crossref_primary_10_2147_BTT_S252581
crossref_primary_10_1253_circj_CJ_18_0687
crossref_primary_10_1002_advs_202302940
crossref_primary_10_1016_j_semcdb_2021_06_019
crossref_primary_10_1016_j_jdermsci_2019_10_002
crossref_primary_10_1038_s41598_020_70979_y
crossref_primary_10_1186_s12967_017_1183_y
crossref_primary_10_1007_s00018_020_03692_8
crossref_primary_10_1186_s41232_019_0106_0
crossref_primary_10_1111_ceo_14128
crossref_primary_10_1126_scitranslmed_aai7471
crossref_primary_10_1016_j_reth_2024_04_008
crossref_primary_10_1172_JCI130767
crossref_primary_10_1038_s12276_020_0482_1
crossref_primary_10_4252_wjsc_v11_i10_787
crossref_primary_10_1186_s13287_018_1036_5
crossref_primary_10_1111_bph_15459
crossref_primary_10_1167_tvst_10_10_13
crossref_primary_10_1016_j_nbt_2021_02_001
crossref_primary_10_1093_brain_awae204
crossref_primary_10_1167_tvst_10_10_17
crossref_primary_10_1016_j_jdsr_2022_03_002
crossref_primary_10_1039_D1TB00976A
crossref_primary_10_1186_s13287_020_01946_7
crossref_primary_10_3390_ph12020065
crossref_primary_10_4252_wjsc_v16_i5_512
crossref_primary_10_1051_medsci_20183405004
crossref_primary_10_1002_term_2770
crossref_primary_10_1038_s41598_024_69917_z
crossref_primary_10_1089_cell_2017_0064
crossref_primary_10_1016_j_xjtc_2022_01_012
crossref_primary_10_2302_kjm_2020_0009_IR
crossref_primary_10_3389_fgene_2024_1389558
crossref_primary_10_1111_gtc_12702
crossref_primary_10_2174_1389201021666200416130253
crossref_primary_10_3390_biology12050737
crossref_primary_10_26599_JNR_2018_9040001
crossref_primary_10_1016_j_cell_2018_09_010
crossref_primary_10_1097_JCMA_0000000000000899
crossref_primary_10_1016_j_biomaterials_2021_121031
crossref_primary_10_4103_hjo_hjo_15_22
crossref_primary_10_3390_jcm11237030
crossref_primary_10_1016_j_stemcr_2017_09_022
crossref_primary_10_1111_cge_13058
crossref_primary_10_1016_j_ajo_2017_04_007
crossref_primary_10_1038_s41419_018_0990_2
crossref_primary_10_1167_iovs_19_27114
crossref_primary_10_12997_jla_2020_9_2_268
crossref_primary_10_1248_yakushi_20_00177_4
crossref_primary_10_1016_j_omtm_2021_02_006
crossref_primary_10_1089_cell_2022_0105
crossref_primary_10_1111_jcmm_18359
crossref_primary_10_1248_yakushi_20_00177_F
crossref_primary_10_3390_cells13141229
crossref_primary_10_1002_hep_31705
crossref_primary_10_3390_ijms20020241
crossref_primary_10_1016_j_jcyt_2025_01_015
crossref_primary_10_1167_iovs_18_24426
crossref_primary_10_1371_journal_pone_0318204
crossref_primary_10_1007_s11095_018_2534_y
crossref_primary_10_1016_j_bbrc_2021_03_012
crossref_primary_10_1016_j_exer_2023_109778
crossref_primary_10_1016_j_jpedsurg_2018_10_027
crossref_primary_10_1155_2023_9099778
crossref_primary_10_1186_s12967_024_05769_5
crossref_primary_10_1016_j_eng_2020_02_004
crossref_primary_10_1186_s13287_025_04196_7
crossref_primary_10_1111_jdi_12758
crossref_primary_10_1016_j_slast_2023_10_004
crossref_primary_10_1007_s00595_017_1610_y
crossref_primary_10_1016_j_biomaterials_2020_120013
crossref_primary_10_1016_j_stemcr_2022_11_019
crossref_primary_10_1002_sctm_20_0007
crossref_primary_10_1007_s12015_022_10366_4
crossref_primary_10_1002_sctm_20_0242
crossref_primary_10_4252_wjsc_v13_i10_1446
crossref_primary_10_3390_cells11081328
crossref_primary_10_1096_fj_201801059
crossref_primary_10_1111_iju_13762
crossref_primary_10_1111_xen_12468
crossref_primary_10_3389_fopht_2024_1377098
crossref_primary_10_1097_APO_0000000000000538
crossref_primary_10_3389_ti_2022_10575
crossref_primary_10_1002_sctm_17_0205
crossref_primary_10_1038_s41684_018_0003_1
crossref_primary_10_2478_bjmg_2020_0003
crossref_primary_10_1038_s41467_024_49335_5
crossref_primary_10_1080_08820538_2024_2363849
crossref_primary_10_1007_s10384_018_0623_4
crossref_primary_10_3389_fimmu_2017_00955
crossref_primary_10_1016_j_isci_2019_100789
crossref_primary_10_1039_D0ME00062K
crossref_primary_10_1167_tvst_13_12_28
crossref_primary_10_3390_biomedicines10112777
crossref_primary_10_1242_dev_202067
crossref_primary_10_1089_ars_2020_8193
crossref_primary_10_1371_journal_pone_0227641
crossref_primary_10_1038_s41598_023_31780_9
crossref_primary_10_1096_fj_202002754R
crossref_primary_10_3390_ijms22147667
crossref_primary_10_1002_stem_3379
crossref_primary_10_15406_jsrt_2017_03_00089
crossref_primary_10_1097_APO_0000000000000521
crossref_primary_10_1186_s41232_020_00132_9
crossref_primary_10_1016_j_aopr_2024_02_001
crossref_primary_10_1016_j_survophthal_2024_05_002
crossref_primary_10_1038_s41598_024_60895_w
crossref_primary_10_1016_j_expneurol_2020_113515
crossref_primary_10_3389_fmed_2017_00229
crossref_primary_10_2174_1574888X17666220621153508
crossref_primary_10_1097_IAE_0000000000004114
crossref_primary_10_1186_s12863_020_00956_x
crossref_primary_10_3390_bioengineering10080983
crossref_primary_10_1088_2516_1091_ab5637
crossref_primary_10_1016_j_jhep_2021_04_048
crossref_primary_10_3390_jcm8111782
crossref_primary_10_1039_D1NR08337F
crossref_primary_10_1002_sctm_20_0278
crossref_primary_10_1167_iovs_18_24229
crossref_primary_10_1016_j_molmed_2022_03_001
crossref_primary_10_3390_pharmaceutics16101299
crossref_primary_10_3389_fbioe_2020_599674
crossref_primary_10_1186_s13287_022_03073_x
crossref_primary_10_1155_2021_2616807
crossref_primary_10_3389_fnins_2021_668857
crossref_primary_10_1002_ehf2_12406
crossref_primary_10_1016_j_amjmed_2017_04_045
crossref_primary_10_1038_s41586_018_0733_7
crossref_primary_10_1016_j_bbrc_2019_08_021
crossref_primary_10_1016_j_pneurobio_2018_04_005
crossref_primary_10_1002_jcla_24464
crossref_primary_10_3390_cells10112951
crossref_primary_10_3389_fcvm_2018_00004
crossref_primary_10_1152_physrev_00039_2017
crossref_primary_10_1038_s41540_022_00231_y
crossref_primary_10_1038_s41586_018_0076_4
crossref_primary_10_1080_13816810_2024_2423784
crossref_primary_10_3390_cells11223567
crossref_primary_10_1016_j_reth_2022_02_004
crossref_primary_10_1016_j_ophtha_2018_04_037
crossref_primary_10_1038_s41582_021_00465_0
crossref_primary_10_1038_d41586_022_02232_7
crossref_primary_10_2174_1574888X16666210622124555
crossref_primary_10_1016_j_addr_2018_05_005
crossref_primary_10_1056_NEJMc1706274
crossref_primary_10_1186_s13036_024_00405_8
crossref_primary_10_1097_APO_0000000000000325
crossref_primary_10_1016_j_stem_2019_02_005
crossref_primary_10_1111_ceo_14309
crossref_primary_10_3390_gels9010024
crossref_primary_10_1038_s41586_018_0089_z
crossref_primary_10_1056_NEJMcibr1615878
crossref_primary_10_15283_ijsc23037
crossref_primary_10_3390_pharmaceutics15102370
crossref_primary_10_1016_j_reth_2024_06_013
crossref_primary_10_3103_S0891416821030034
crossref_primary_10_1038_s41551_019_0471_7
crossref_primary_10_1186_s13287_024_03690_8
crossref_primary_10_1056_NEJMra1716145
crossref_primary_10_23868_gc346688
crossref_primary_10_1016_j_stem_2024_05_005
crossref_primary_10_1016_j_tibtech_2020_07_006
crossref_primary_10_1007_s12015_024_10783_7
crossref_primary_10_1016_j_stem_2021_07_012
crossref_primary_10_1007_s13770_023_00555_8
crossref_primary_10_1038_s41598_022_05006_3
crossref_primary_10_1210_clinem_dgaa986
crossref_primary_10_1016_j_biochi_2023_12_011
crossref_primary_10_1167_iovs_18_24828
crossref_primary_10_1186_s41232_020_00125_8
crossref_primary_10_4254_wjh_v10_i10_702
crossref_primary_10_1186_s12348_022_00305_2
crossref_primary_10_1111_cpr_13100
crossref_primary_10_1016_j_ceb_2018_05_006
crossref_primary_10_1016_j_copbio_2018_03_011
crossref_primary_10_26599_JNR_2021_9040005
crossref_primary_10_1371_journal_pone_0201683
crossref_primary_10_1002_stem_2797
crossref_primary_10_1016_S0140_6736_24_01764_1
crossref_primary_10_1038_s41467_025_55882_2
crossref_primary_10_1242_dev_182642
crossref_primary_10_1111_bpa_12626
crossref_primary_10_1016_j_stem_2019_10_001
crossref_primary_10_1016_j_copbio_2018_03_006
crossref_primary_10_1089_genbio_2022_0001
crossref_primary_10_3233_JPD_212608
crossref_primary_10_1016_j_btre_2022_e00708
crossref_primary_10_1016_j_preteyeres_2018_09_002
crossref_primary_10_3950_jibiinkotokeibu_125_8_1281
crossref_primary_10_1002_jcp_27194
crossref_primary_10_1016_j_ophtha_2017_12_037
crossref_primary_10_1016_j_bbrc_2018_10_020
crossref_primary_10_3389_fcell_2020_00743
crossref_primary_10_1016_j_preteyeres_2020_100846
crossref_primary_10_1161_STROKEAHA_117_019216
crossref_primary_10_1186_s13287_024_04052_0
crossref_primary_10_3390_jcm13082417
crossref_primary_10_1016_j_ejpb_2018_02_013
crossref_primary_10_1016_j_preteyeres_2022_101063
crossref_primary_10_1038_s41587_024_02196_1
crossref_primary_10_1016_j_medj_2022_10_003
crossref_primary_10_1007_s40778_018_0148_2
crossref_primary_10_1186_s10020_023_00691_w
crossref_primary_10_1016_j_preteyeres_2022_101065
crossref_primary_10_2217_rme_2022_0045
crossref_primary_10_1038_ncb3598
crossref_primary_10_1002_sctm_18_0026
crossref_primary_10_1371_journal_pone_0292238
crossref_primary_10_1360_SSV_2021_0276
crossref_primary_10_1007_s12015_024_10717_3
crossref_primary_10_1016_j_reth_2024_09_001
crossref_primary_10_1038_d41586_019_02834_8
crossref_primary_10_1186_s13287_023_03322_7
crossref_primary_10_2217_nnm_2018_0299
crossref_primary_10_1186_s13287_023_03564_5
crossref_primary_10_1007_s13577_021_00592_2
crossref_primary_10_1038_d41586_025_00659_2
crossref_primary_10_1134_S0026893319050042
crossref_primary_10_2217_rme_2017_0130
crossref_primary_10_3390_cells8111438
crossref_primary_10_1089_scd_2017_0132
crossref_primary_10_1038_s41592_018_0113_0
crossref_primary_10_1134_S0006297924050031
crossref_primary_10_3389_fimmu_2017_00645
crossref_primary_10_1016_j_jtcvs_2018_04_018
crossref_primary_10_1093_database_baab038
crossref_primary_10_3389_fnins_2022_884667
crossref_primary_10_18632_oncotarget_24030
crossref_primary_10_1097_IIO_0000000000000250
crossref_primary_10_1080_08164622_2024_2361752
crossref_primary_10_1016_j_reth_2024_08_012
crossref_primary_10_1007_s40472_018_0177_x
crossref_primary_10_1016_j_bbrep_2021_100979
crossref_primary_10_1097_IAE_0000000000002449
crossref_primary_10_1007_s11825_017_0140_8
crossref_primary_10_1172_JCI131187
crossref_primary_10_1038_s41467_022_35180_x
crossref_primary_10_12936_tenrikiyo_22_001
crossref_primary_10_1016_j_preteyeres_2021_100950
crossref_primary_10_1038_s41419_019_1957_7
crossref_primary_10_1002_stem_2754
crossref_primary_10_1038_s41409_019_0704_0
crossref_primary_10_1007_s12015_020_10061_2
crossref_primary_10_1016_j_neuropharm_2019_107781
crossref_primary_10_3390_ijms21197309
crossref_primary_10_1038_s41467_020_15326_5
crossref_primary_10_1002_sctm_18_0282
crossref_primary_10_1186_s13287_022_02712_7
crossref_primary_10_3389_fncel_2021_761416
crossref_primary_10_1016_j_reth_2024_08_024
crossref_primary_10_1089_hgtb_2017_082
crossref_primary_10_2217_epi_2023_0281
crossref_primary_10_1016_j_jcyt_2018_03_037
crossref_primary_10_1126_scitranslmed_aao4097
crossref_primary_10_2174_1566523221666210707123809
crossref_primary_10_1111_febs_16162
crossref_primary_10_1038_s41598_018_19264_7
crossref_primary_10_1016_j_biologicals_2020_10_001
crossref_primary_10_1007_s00347_022_01631_5
crossref_primary_10_1038_s41598_019_51944_w
crossref_primary_10_1101_cshperspect_a035683
crossref_primary_10_1002_glia_23733
crossref_primary_10_1016_j_jbiosc_2023_12_008
crossref_primary_10_1038_s41577_019_0200_1
crossref_primary_10_1007_s40778_021_00197_3
crossref_primary_10_3390_ijms241914408
crossref_primary_10_1016_j_bmcl_2022_128601
crossref_primary_10_1186_s12916_022_02710_9
crossref_primary_10_3390_ijms20246305
crossref_primary_10_3390_ijms222212555
crossref_primary_10_3389_fbioe_2020_588014
crossref_primary_10_1186_s41232_020_00145_4
crossref_primary_10_3389_fmed_2022_813952
crossref_primary_10_1016_j_preteyeres_2019_03_001
crossref_primary_10_1089_biores_2018_0028
crossref_primary_10_1007_s11892_018_0971_y
crossref_primary_10_1155_2018_5056279
crossref_primary_10_1016_j_clae_2019_04_006
crossref_primary_10_1016_j_isci_2021_103290
crossref_primary_10_1016_j_scr_2019_101514
crossref_primary_10_3390_biology14030314
crossref_primary_10_1186_s13287_022_02965_2
crossref_primary_10_1155_sci_6153235
crossref_primary_10_1371_journal_pone_0212369
crossref_primary_10_1360_SSV_2021_0075
crossref_primary_10_3390_bioengineering9070297
crossref_primary_10_1016_j_neurobiolaging_2024_04_012
crossref_primary_10_3389_fnagi_2018_00077
crossref_primary_10_1016_j_biomaterials_2018_10_027
crossref_primary_10_3389_fimmu_2017_00870
crossref_primary_10_1016_j_stemcr_2024_06_004
crossref_primary_10_1111_dgd_12704
crossref_primary_10_1155_2022_9717599
crossref_primary_10_1080_1061186X_2024_2433563
crossref_primary_10_1080_17474124_2019_1618186
crossref_primary_10_3389_fncel_2020_00179
crossref_primary_10_1111_jcmm_14669
crossref_primary_10_1016_j_ydbio_2017_09_028
crossref_primary_10_1089_ten_tea_2024_0112
crossref_primary_10_1093_stcltm_szad069
crossref_primary_10_1038_s41598_020_66845_6
crossref_primary_10_1039_C9TB01764J
crossref_primary_10_1016_j_stemcr_2021_08_017
crossref_primary_10_3389_fbioe_2022_905516
crossref_primary_10_1016_j_cell_2020_11_034
crossref_primary_10_1538_expanim_17_0095
crossref_primary_10_1007_s40135_021_00275_z
crossref_primary_10_3389_fncel_2020_00171
crossref_primary_10_1097_JCMA_0000000000001046
crossref_primary_10_1111_resp_14007
crossref_primary_10_1002_advs_202301639
crossref_primary_10_1016_j_scr_2018_01_014
crossref_primary_10_1016_j_stemcr_2025_102424
crossref_primary_10_3389_fphar_2022_796380
crossref_primary_10_1016_j_stemcr_2025_102425
crossref_primary_10_1016_j_preteyeres_2017_10_004
crossref_primary_10_1186_s13287_017_0652_9
crossref_primary_10_3390_jcm10051124
crossref_primary_10_1016_j_celrep_2017_08_003
crossref_primary_10_1089_scd_2018_0118
crossref_primary_10_1136_medethics_2018_105024
crossref_primary_10_1038_s41598_020_65657_y
crossref_primary_10_3390_biomedicines10020208
crossref_primary_10_1038_s41598_021_85631_6
crossref_primary_10_1089_biores_2019_0046
crossref_primary_10_1371_journal_pone_0235827
crossref_primary_10_3390_ijms24032298
crossref_primary_10_1089_ten_tec_2019_0136
crossref_primary_10_1262_jrd_2019_002
crossref_primary_10_1016_j_actbio_2022_07_064
crossref_primary_10_1038_s10038_017_0348_0
crossref_primary_10_1016_j_tibtech_2017_06_016
crossref_primary_10_1007_s12015_018_9837_6
crossref_primary_10_1080_13543784_2020_1757647
crossref_primary_10_1155_2020_8867349
crossref_primary_10_17116_oftalma2023139051113
crossref_primary_10_3390_ijms21072481
crossref_primary_10_1080_14686996_2021_1938212
crossref_primary_10_1002_stem_2966
crossref_primary_10_1016_j_nut_2021_111275
crossref_primary_10_4103_tcmj_tcmj_145_22
crossref_primary_10_1089_genbio_2021_0010
crossref_primary_10_1016_j_stemcr_2021_09_017
crossref_primary_10_1016_j_scr_2021_102355
crossref_primary_10_2485_jhtb_30_151
crossref_primary_10_1038_s41467_021_21801_4
crossref_primary_10_1093_stcltm_szad028
crossref_primary_10_1007_s13311_019_00728_1
crossref_primary_10_3390_ijms222413674
crossref_primary_10_1007_s10384_018_00644_5
crossref_primary_10_1091_mbc_E19_03_0135
crossref_primary_10_14341_WJPM9297
crossref_primary_10_1016_j_bbrc_2019_05_186
crossref_primary_10_1002_ctm2_1646
crossref_primary_10_1016_j_reth_2020_03_017
crossref_primary_10_1161_CIRCRESAHA_118_314336
crossref_primary_10_1007_s40883_020_00147_1
crossref_primary_10_3390_cells10113250
crossref_primary_10_1101_cshperspect_a041295
crossref_primary_10_1016_j_banm_2020_07_051
crossref_primary_10_1126_scitranslmed_aaz2253
crossref_primary_10_1093_stcltm_szad039
crossref_primary_10_3390_cells9071717
crossref_primary_10_1093_humupd_dmx042
crossref_primary_10_1016_j_preteyeres_2019_06_002
crossref_primary_10_1038_s12276_025_01422_3
crossref_primary_10_3390_cells10113246
crossref_primary_10_1080_17469899_2018_1555034
crossref_primary_10_3390_cells13181549
crossref_primary_10_1038_nature_2017_21730
crossref_primary_10_21307_ane_2020_024
crossref_primary_10_31083_j_fbl2703106
crossref_primary_10_1016_j_ejphar_2021_174568
crossref_primary_10_1146_annurev_bioeng_010220_113008
crossref_primary_10_3390_ijms21217831
crossref_primary_10_4103_tcmj_tcmj_147_19
crossref_primary_10_1016_j_reth_2020_10_007
crossref_primary_10_17116_molgen2021390313
crossref_primary_10_1016_j_smaim_2022_09_002
crossref_primary_10_1159_000512721
crossref_primary_10_3390_ijms232213794
crossref_primary_10_1186_s13287_022_02961_6
crossref_primary_10_2147_BTT_S290331
crossref_primary_10_1136_bmjophth_2022_000981
crossref_primary_10_1016_j_stem_2018_05_013
crossref_primary_10_1111_bjh_17297
crossref_primary_10_1021_acs_chemrev_0c00342
crossref_primary_10_1016_j_ymeth_2019_09_016
crossref_primary_10_1080_14712598_2017_1346079
crossref_primary_10_1002_stem_2926
crossref_primary_10_7554_eLife_92510
crossref_primary_10_1007_s12015_024_10689_4
crossref_primary_10_1080_14712598_2023_2225701
crossref_primary_10_1016_j_jdsr_2021_03_002
crossref_primary_10_1016_j_stemcr_2024_04_007
crossref_primary_10_2217_rme_2022_0010
crossref_primary_10_1002_term_2870
crossref_primary_10_1101_cshperspect_a041308
crossref_primary_10_1101_cshperspect_a041309
crossref_primary_10_1016_j_ymthe_2018_02_026
crossref_primary_10_3389_fimmu_2021_662360
crossref_primary_10_1016_j_stem_2020_09_014
crossref_primary_10_1039_D2TB02521C
crossref_primary_10_1016_j_ophtha_2019_03_019
crossref_primary_10_1093_brain_awac358
crossref_primary_10_1541_ieejjournal_139_164
crossref_primary_10_1007_s00795_018_0211_1
crossref_primary_10_1016_j_isci_2022_105050
crossref_primary_10_1016_j_jnrt_2022_100015
crossref_primary_10_1186_s13287_017_0584_4
crossref_primary_10_1080_17469899_2023_2296895
crossref_primary_10_2463_mrms_rev_2024_0007
crossref_primary_10_1016_j_oret_2019_09_017
crossref_primary_10_3390_cells10020240
crossref_primary_10_1136_jitc_2020_000756
crossref_primary_10_1016_j_ebiom_2020_102848
crossref_primary_10_1016_j_addr_2025_115525
crossref_primary_10_1515_mr_2023_0060
crossref_primary_10_1002_jgm_3015
crossref_primary_10_1039_D2TB00583B
crossref_primary_10_1002_sctm_20_0522
crossref_primary_10_1089_ten_tea_2020_0273
crossref_primary_10_1002_ecj_12393
crossref_primary_10_1134_S0006297918090067
crossref_primary_10_1080_17469899_2019_1568872
crossref_primary_10_3390_cells12020211
crossref_primary_10_1016_j_bbmt_2019_09_009
crossref_primary_10_3390_cells10092319
crossref_primary_10_1007_s12015_020_10090_x
crossref_primary_10_1097_IIO_0000000000000510
crossref_primary_10_1186_s13287_023_03612_0
crossref_primary_10_3389_fnagi_2022_948279
crossref_primary_10_1038_s12276_021_00588_w
crossref_primary_10_1016_j_stemcr_2020_01_006
crossref_primary_10_31348_2019_6_1
crossref_primary_10_2745_dds_38_356
crossref_primary_10_3390_ijms25158060
crossref_primary_10_1002_sctm_17_0169
crossref_primary_10_1038_s41467_018_05067_x
crossref_primary_10_1089_ten_tea_2020_0265
crossref_primary_10_1002_term_2615
crossref_primary_10_3390_cells8010026
crossref_primary_10_1016_j_exger_2020_110893
crossref_primary_10_1007_s11033_021_06489_5
crossref_primary_10_1007_s11427_023_2531_3
crossref_primary_10_1111_exd_14292
crossref_primary_10_3390_ijms25094793
crossref_primary_10_1021_acs_analchem_2c04416
crossref_primary_10_1177_09636897221104451
crossref_primary_10_1016_j_ymthe_2024_06_014
crossref_primary_10_1016_j_exer_2018_07_019
crossref_primary_10_1016_j_addr_2020_09_010
crossref_primary_10_1016_j_jcyt_2024_05_022
crossref_primary_10_1016_j_reth_2023_03_004
crossref_primary_10_3389_fimmu_2022_869514
crossref_primary_10_1016_j_stemcr_2021_09_001
crossref_primary_10_7554_eLife_67660
crossref_primary_10_1016_j_molmed_2019_07_004
crossref_primary_10_3390_ijms22083990
crossref_primary_10_1016_j_lfs_2018_09_057
crossref_primary_10_2217_epi_2020_0409
crossref_primary_10_3389_fbioe_2023_1205122
crossref_primary_10_1016_j_crmeth_2021_100087
crossref_primary_10_1038_s44222_024_00220_2
crossref_primary_10_1016_j_stemcr_2017_10_003
crossref_primary_10_1016_j_mad_2023_111854
crossref_primary_10_1016_j_exer_2019_107883
crossref_primary_10_3390_ijms21176066
crossref_primary_10_1038_s12276_024_01334_8
crossref_primary_10_1016_j_stemcr_2019_04_016
crossref_primary_10_1016_j_omtm_2022_05_010
crossref_primary_10_3390_ijms21093077
crossref_primary_10_1097_ICU_0000000000000838
crossref_primary_10_3233_STJ_200002
crossref_primary_10_3390_cells8050403
crossref_primary_10_1126_scitranslmed_aan2783
crossref_primary_10_3390_life14060668
crossref_primary_10_1007_s40778_018_0140_x
crossref_primary_10_1177_09636897221085901
crossref_primary_10_1186_s12967_023_03937_7
crossref_primary_10_7554_eLife_92510_3
crossref_primary_10_1016_j_regen_2022_100064
crossref_primary_10_3389_fcell_2019_00128
crossref_primary_10_3390_ijms23052529
crossref_primary_10_1038_nbt_4118
crossref_primary_10_1038_nbt_4114
crossref_primary_10_1016_j_coph_2018_07_007
crossref_primary_10_1097_TP_0000000000001937
crossref_primary_10_1063_1_5109966
crossref_primary_10_3390_cells11030529
crossref_primary_10_1080_14728214_2021_1931120
crossref_primary_10_3390_ijms20010178
crossref_primary_10_3390_ijms22031095
crossref_primary_10_1016_j_stemcr_2022_03_019
crossref_primary_10_1186_s13287_020_02122_7
crossref_primary_10_1016_j_ymthe_2020_01_023
crossref_primary_10_1016_j_biomaterials_2022_121459
crossref_primary_10_3390_ijms251910485
crossref_primary_10_1097_j_pain_0000000000001733
crossref_primary_10_1177_09636897231173734
crossref_primary_10_1093_lifemedi_lnad027
crossref_primary_10_3390_cells10112888
crossref_primary_10_1007_s13238_019_00665_x
crossref_primary_10_1016_j_exer_2020_108283
crossref_primary_10_1016_j_stemcr_2021_12_008
crossref_primary_10_3390_ijms221910497
crossref_primary_10_3390_ijms24087297
crossref_primary_10_1038_s41598_020_60466_9
crossref_primary_10_1242_dev_153569
crossref_primary_10_1111_jcmm_14292
crossref_primary_10_1016_j_preteyeres_2018_06_002
crossref_primary_10_1186_s13287_021_02301_0
crossref_primary_10_1016_j_mcp_2018_01_001
crossref_primary_10_3390_cells10010049
crossref_primary_10_1038_s41586_018_0073_7
crossref_primary_10_1016_j_isci_2020_101535
crossref_primary_10_1097_IIO_0000000000000334
crossref_primary_10_1002_btm2_10114
crossref_primary_10_3390_bioengineering11020179
crossref_primary_10_1002_sctm_21_0080
crossref_primary_10_1038_s41598_022_24725_1
crossref_primary_10_1186_s12967_023_04785_1
crossref_primary_10_25208_vdv551_2020_96_1_10_17
crossref_primary_10_4103_1673_5374_335689
crossref_primary_10_2217_rme_2018_0011
crossref_primary_10_3390_genes10090654
crossref_primary_10_1136_bjophthalmol_2016_309975
crossref_primary_10_1002_adhm_201800226
crossref_primary_10_1038_s41467_018_04609_7
crossref_primary_10_1016_j_yjmcc_2021_10_005
crossref_primary_10_1007_s40266_020_00822_6
crossref_primary_10_1016_j_jjcc_2018_05_002
crossref_primary_10_3389_fphys_2023_1344885
crossref_primary_10_1186_s13287_023_03434_0
crossref_primary_10_1002_sctm_18_0087
crossref_primary_10_1002_sctm_18_0084
crossref_primary_10_1186_s13287_023_03556_5
crossref_primary_10_1016_j_preteyeres_2020_100918
crossref_primary_10_3389_fbioe_2023_1269385
crossref_primary_10_14348_molcells_2021_0078
crossref_primary_10_1016_j_gendis_2021_02_009
crossref_primary_10_1016_j_addr_2020_08_007
crossref_primary_10_1038_s41467_020_17285_3
crossref_primary_10_3390_genes9120575
crossref_primary_10_1080_14636778_2020_1778459
crossref_primary_10_3390_jcm8040476
crossref_primary_10_1042_BST20230794
crossref_primary_10_1016_j_reth_2024_11_008
crossref_primary_10_3389_fcell_2021_748576
crossref_primary_10_1016_j_xops_2022_100216
crossref_primary_10_1093_intimm_dxad008
crossref_primary_10_2174_1574888X15666191218094020
crossref_primary_10_3389_fchem_2019_00298
crossref_primary_10_1177_0271678X20910324
crossref_primary_10_1007_s10384_022_00974_5
crossref_primary_10_1186_s13287_021_02134_x
crossref_primary_10_1089_ten_teb_2023_0053
crossref_primary_10_1016_j_scr_2020_101887
crossref_primary_10_1002_stem_3269
crossref_primary_10_3390_pharmaceutics13060865
crossref_primary_10_15252_emmm_201808861
crossref_primary_10_1080_17425247_2021_1888925
crossref_primary_10_3390_ijms22063237
crossref_primary_10_1371_journal_pone_0282174
crossref_primary_10_1016_j_stemcr_2018_09_002
crossref_primary_10_3390_cells9061349
crossref_primary_10_3390_genes12010112
crossref_primary_10_4103_1673_5374_280303
crossref_primary_10_1083_jcb_201909163
crossref_primary_10_1002_advs_202101837
crossref_primary_10_1167_iovs_62_13_8
crossref_primary_10_1177_17562872211002059
crossref_primary_10_1016_j_oret_2019_04_021
crossref_primary_10_1016_j_xgen_2023_100302
crossref_primary_10_1002_stem_3017
crossref_primary_10_3390_cells9112517
crossref_primary_10_3390_molecules25245809
crossref_primary_10_1155_2020_3692937
crossref_primary_10_1007_s12015_019_09935_x
crossref_primary_10_1016_j_exphem_2019_01_005
crossref_primary_10_1177_2472630320972110
crossref_primary_10_1016_j_molmed_2021_01_001
crossref_primary_10_1007_s10384_018_0611_8
crossref_primary_10_1016_j_actbio_2017_11_058
crossref_primary_10_1177_2474126420971982
crossref_primary_10_1016_j_jcyt_2024_02_022
crossref_primary_10_1159_000541919
crossref_primary_10_1038_s41598_022_19777_2
crossref_primary_10_1177_2515841418817490
crossref_primary_10_1038_s41598_019_55130_w
crossref_primary_10_1186_s40169_020_0268_z
crossref_primary_10_3390_jcm9072217
crossref_primary_10_1038_s41598_020_58296_w
crossref_primary_10_1177_2472630320972109
crossref_primary_10_1186_s13287_023_03576_1
crossref_primary_10_1038_s41536_020_00100_4
crossref_primary_10_3390_cells13010076
crossref_primary_10_1016_j_celrep_2024_114006
crossref_primary_10_1016_j_preteyeres_2019_100779
crossref_primary_10_1016_j_ebiom_2017_03_042
crossref_primary_10_31857_S0320972524050036
crossref_primary_10_1007_s12015_020_10042_5
crossref_primary_10_1155_2019_5171032
crossref_primary_10_1111_cns_13247
crossref_primary_10_1038_s41588_022_01147_3
crossref_primary_10_3390_cells10040743
crossref_primary_10_1177_0963689718773363
crossref_primary_10_3390_bioengineering9120791
crossref_primary_10_3389_fcvm_2018_00109
crossref_primary_10_2342_ymj_72_69
crossref_primary_10_1111_asj_13272
crossref_primary_10_1016_j_mcn_2020_103571
crossref_primary_10_1039_C9BM00418A
crossref_primary_10_1242_dev_133108
crossref_primary_10_3390_genes9050265
crossref_primary_10_1016_j_aej_2023_08_080
crossref_primary_10_3390_ijms21124273
crossref_primary_10_26599_JNR_2020_9040009
crossref_primary_10_1186_s13287_017_0738_4
crossref_primary_10_1093_rb_rbaf003
crossref_primary_10_3389_fcell_2021_737242
crossref_primary_10_1007_s13346_020_00753_0
crossref_primary_10_1016_j_drudis_2018_10_007
crossref_primary_10_1002_adhm_202202114
crossref_primary_10_1007_s12015_024_10802_7
crossref_primary_10_1016_j_cis_2024_103337
crossref_primary_10_1016_j_stem_2020_10_014
crossref_primary_10_1016_j_stemcr_2020_02_006
crossref_primary_10_1016_j_stemcr_2021_10_017
crossref_primary_10_34133_2020_1658678
crossref_primary_10_2147_EB_S307551
crossref_primary_10_1016_j_fmre_2023_08_011
crossref_primary_10_3950_jibiinkoka_121_853
crossref_primary_10_1007_s00429_018_1702_5
crossref_primary_10_1016_j_stemcr_2019_01_018
crossref_primary_10_3390_jpm11060565
crossref_primary_10_1016_j_semcdb_2022_09_011
crossref_primary_10_1002_term_2805
crossref_primary_10_1371_journal_pgen_1009628
crossref_primary_10_1016_j_oret_2020_06_012
crossref_primary_10_4103_1673_5374_361537
crossref_primary_10_1186_s12967_023_04501_z
Cites_doi 10.1167/iovs.04-0118
10.1016/S0161-6420(95)31034-2
10.1016/S0161-6420(95)30846-9
10.1056/NEJMoa054481
10.1016/j.ophtha.2013.03.046
10.1016/j.stemcr.2014.03.011
10.1136/bjo.88.1.110
10.1371/journal.pone.0037342
10.1001/archophthalmol.2009.326
10.1167/iovs.14-15619
10.1016/j.stemcr.2013.12.007
10.1016/S0161-6420(92)31871-8
10.1016/j.neulet.2009.04.035
10.1016/j.ajo.2003.11.026
10.1177/112067219900900310
10.1016/j.ophtha.2004.07.021
10.1016/S0140-6736(12)60028-2
10.1016/j.ajo.2011.06.007
10.1001/archopht.1994.01090160076025
10.1038/sj.eye.6702823
10.1038/nature09971
10.1056/NEJM200002173420707
10.1007/s00417-005-0184-3
10.1136/bjo.85.10.1153
10.1016/j.stemcr.2015.04.005
10.1073/pnas.1512590113
10.1016/S0002-9394(03)00384-2
10.1073/pnas.172398299
10.1136/bjo.2009.176305
10.1016/S0140-6736(14)61376-3
ContentType Journal Article
Copyright Copyright © 2017 Massachusetts Medical Society. All rights reserved.
Copyright_xml – notice: Copyright © 2017 Massachusetts Medical Society. All rights reserved.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7RV
7X7
7XB
8AO
8C1
8FE
8FH
8FI
ABUWG
AFKRA
AN0
AZQEC
BBNVY
BEC
BENPR
BHPHI
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
GUQSH
HCIFZ
K0Y
LK8
M0R
M0T
M1P
M2M
M2O
M2P
M7P
MBDVC
NAPCQ
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
PSYQQ
Q9U
7X8
DOI 10.1056/NEJMoa1608368
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Nursing & Allied Health Database
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
ProQuest Pharma Collection
Public Health Database
ProQuest SciTech Collection
ProQuest Natural Science Collection
Hospital Premium Collection
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
British Nursing Database
ProQuest Central Essentials
Biological Science Collection
eLibrary
ProQuest Central
Natural Science Collection
ProQuest One
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
ProQuest Research Library
SciTech Premium Collection
New England Journal of Medicine
ProQuest Biological Science Collection
Consumer Health Database
Healthcare Administration Database
Medical Database
Psychology Database
Research Library
Science Database
Biological Science Database
Research Library (Corporate)
Nursing & Allied Health Premium
ProQuest Central Premium
ProQuest One Academic (New)
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest One Psychology
ProQuest Central Basic
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest One Psychology
Research Library Prep
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
elibrary
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
New England Journal of Medicine
ProQuest Natural Science Collection
ProQuest Pharma Collection
ProQuest Central China
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Natural Science Collection
ProQuest Central Korea
Health & Medical Research Collection
Biological Science Collection
ProQuest Research Library
ProQuest Central (New)
ProQuest Public Health
ProQuest Biological Science Collection
ProQuest Central Basic
ProQuest Science Journals
ProQuest Family Health
ProQuest One Academic Eastern Edition
British Nursing Index with Full Text
ProQuest Health Management
ProQuest Nursing & Allied Health Source
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
Nursing & Allied Health Premium
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest Psychology Journals
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
ProQuest One Psychology

MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1533-4406
EndPage 1046
ExternalDocumentID 4321996501
28296613
10_1056_NEJMoa1608368
NJ201703163761108
Genre Original Article
Research Support, Non-U.S. Gov't
Journal Article
Case Reports
GeographicLocations Japan
GeographicLocations_xml – name: Japan
GroupedDBID -
0R
0WA
123
186
1VV
29N
2KS
2WC
34G
39C
3V.
4
4.4
53G
55
5RE
7FN
7RV
7X7
85S
8AO
8C1
8FE
8FH
8FI
AACLI
AAEJM
AAIKC
AALRV
AAPBV
AAQQT
AARDX
AAWTL
ABACO
ABEHJ
ABFLS
ABIVO
ABOCM
ABPPZ
ABPTK
ABQIJ
ABUWG
ABWJO
ACGFS
ACGOD
ACJLH
ACNCT
ACPRK
ACRZS
ADBBV
ADBIT
ADCBC
ADRHT
AENEX
AETEA
AFFNX
AFHKK
AFKRA
AGFXO
AGNAY
AHMBA
AJJEV
AJVPN
ALMA_UNASSIGNED_HOLDINGS
AN0
AQUVI
AZQEC
BBAFP
BBNVY
BCU
BENPR
BES
BHPHI
BKEYQ
BKNYI
BLC
BNQBC
BPHCQ
BVXVI
C45
CJ0
CO
CS3
DCD
DU5
DWQXO
DZ
EBS
EJD
ET
EX3
F5P
FD8
FM.
FYUFA
GJ
GNUQQ
GUQSH
H13
HCIFZ
HZ
I4R
IH2
K-O
KM
KOO
L7B
LK8
M0R
M0T
M1P
M2M
M2O
M2P
M7P
MVM
N9A
NAPCQ
NEJ
O9-
OK1
OMK
OVD
P-O
P-S
P2P
PADUT
PCD
PQEST
PQQKQ
PQUKI
PRINS
PROAC
PSQYO
QJJ
RHI
RWL
RXW
S10
S6N
SJFOW
SJN
TAE
TAF
TEORI
TN5
TUQ
TWZ
UCV
UKR
UMD
VQA
W2G
WH7
WOQ
WOW
X
X7M
XJT
XYN
XZL
YCJ
YNT
YRY
YZZ
ZA5
ZHY
ZR0
---
-DZ
-ET
-~X
.-4
.55
.CO
.GJ
0R~
36B
AAMNW
AAQOH
AAYXX
ABBLC
ABCQX
ABDQB
ABJNI
ACKOT
ACPFK
ADUKH
AERZD
AFOSN
AGHSJ
ALIPV
BYPQX
CCPQU
CITATION
HF~
HMCUK
HZ~
N4W
PHGZM
PHGZT
PSYQQ
UKHRP
YFH
YR2
YR5
YYP
ZCA
ZVN
~KM
CGR
CUY
CVF
ECM
EIF
NPM
UIG
7XB
BEC
K0Y
MBDVC
PJZUB
PKEHL
PPXIY
PQGLB
Q9U
7X8
ID FETCH-LOGICAL-c456t-d1568bd55c77b6cc158549f55a9cdfae75965d422962917c0848d3e978e361653
IEDL.DBID 7X7
ISSN 0028-4793
1533-4406
IngestDate Mon Jul 21 11:01:16 EDT 2025
Sat Aug 23 13:18:05 EDT 2025
Thu Apr 03 07:03:55 EDT 2025
Thu Apr 24 23:01:22 EDT 2025
Tue Jul 01 01:43:19 EDT 2025
Tue Dec 21 14:38:55 EST 2021
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 11
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c456t-d1568bd55c77b6cc158549f55a9cdfae75965d422962917c0848d3e978e361653
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Case Study-2
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
OpenAccessLink https://www.nejm.org/doi/pdf/10.1056/NEJMoa1608368?articleTools=true
PMID 28296613
PQID 1891886882
PQPubID 40644
PageCount 9
ParticipantIDs proquest_miscellaneous_1878179668
proquest_journals_1891886882
pubmed_primary_28296613
crossref_primary_10_1056_NEJMoa1608368
crossref_citationtrail_10_1056_NEJMoa1608368
mms_nejm_10_1056_NEJMoa1608368
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 20170316
2017-03-16
PublicationDateYYYYMMDD 2017-03-16
PublicationDate_xml – month: 03
  year: 2017
  text: 20170316
  day: 16
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: Boston
PublicationSeriesTitle Brief Report
PublicationTitle The New England journal of medicine
PublicationTitleAlternate N Engl J Med
PublicationYear 2017
Publisher Massachusetts Medical Society
Publisher_xml – name: Massachusetts Medical Society
References Mitchell, P, Smith, W, Attebo, K, Wang, JJ (r004) 1995; 102
Assawachananont, J, Mandai, M, Okamoto, S (r029) 2014; 2
Peyman, GA, Blinder, KJ, Paris, CL, Alturki, W, Nelson, NC, Desai, U (r013) 1991; 22
Holz, FG, Pauleikhoff, D, Klein, R, Bird, AC (r006) 2004; 137
Zweifel, SA, Engelbert, M, Laud, K, Margolis, R, Spaide, RF, Freund, KB (r026) 2009; 127
Zhao, T, Zhang, Z-N, Rong, Z, Xu, Y (r027) 2011; 474
Heussen, FM, Fawzy, NF, Joeres, S (r018) 2008; 22
Vingerling, JR, Dielemans, I, Hofman, A (r003) 1995; 102
Rofagha, S, Bhisitkul, RB, Boyer, DS, Sadda, SR, Zhang, K (r009) 2013; 120
Hirami, Y, Osakada, F, Takahashi, K (r024) 2009; 458
Hawkins, BS, Bressler, NM, Miskala, PH (r011) 2004; 111
Shirai, H, Mandai, M, Matsushita, K (r030) 2016; 113
Kamao, H, Mandai, M, Okamoto, S (r025) 2014; 2
Rosenfeld, PJ, Brown, DM, Heier, JS (r007) 2006; 355
Binder, S, Krebs, I, Hilgers, R-D (r015) 2004; 45
Algvere, PV, Gouras, P, Dafgård Kopp, E (r014) 1999; 9
Holash, J, Davis, S, Papadopoulos, N (r008) 2002; 99
van Meurs, JC, ter Averst, E, Hofland, LJ (r016) 2004; 88
Oshima, Y, Ishibashi, T, Murata, T, Tahara, Y, Kiyohara, Y, Kubota, T (r005) 2001; 85
Schwartz, SD, Regillo, CD, Lam, BL (r021) 2015; 385
Schwartz, SD, Hubschman, J-P, Heilwell, G (r022) 2012; 379
van Meurs, JC, Van Den Biesen, PR (r017) 2003; 136
Klein, R, Klein, BE, Linton, KL (r002) 1992; 99
Falkner, CI, Leitich, H, Frommlet, F, Bauer, P, Binder, S (r012) 2007; 245
Kuroda, T, Yasuda, S, Kusakawa, S (r031) 2012; 7
Fine, SL, Berger, JW, Maguire, MG, Ho, AC (r001) 2000; 342
Falkner-Radler, CI, Krebs, I, Glittenberg, C (r020) 2011; 95
Sugita, S, Kamao, H, Iwasaki, Y (r028) 2015; 56
van Zeeburg, EJT, Maaijwee, KJM, Missotten, TOAR, Heimann, H, van Meurs, JC (r019) 2012; 153
Song, WK, Park, K-M, Kim, H-J (r023) 2015; 4
(r010) 1994; 112
r020
r021
r022
r001
Peyman GA (r013) 1991; 22
r023
r017
r018
Algvere PV (r014) 1999; 9
r019
r015
r016
r031
r010
r011
r012
r030
r006
r028
r007
r029
r008
r009
r002
r024
r003
r025
r004
r026
r005
r027
28836423 - N Engl J Med. ;377(8):792
30185969 - Nature. 2018 Sep;561(7721):S1
28446683 - Sci Transl Med. 2017 Apr 26;9(387)
References_xml – volume: 22
  start-page: 799
  year: 2008
  end-page: 807
  ident: r018
  article-title: Autologous translocation of the choroid and RPE in age-related macular degeneration: 1-year follow-up in 30 patients and recommendations for patient selection.
  publication-title: Eye (Lond)
– volume: 102
  start-page: 205
  year: 1995
  end-page: 210
  ident: r003
  article-title: The prevalence of age-related maculopathy in the Rotterdam Study.
  publication-title: Ophthalmology
– volume: 7
  start-page: e37342
  year: 2012
  end-page: e37342
  ident: r031
  article-title: Highly sensitive in vitro methods for detection of residual undifferentiated cells in retinal pigment epithelial cells derived from human iPS cells.
  publication-title: PLoS One
– volume: 127
  start-page: 1596
  year: 2009
  end-page: 1602
  ident: r026
  article-title: Outer retinal tubulation: a novel optical coherence tomography finding.
  publication-title: Arch Ophthalmol
– volume: 153
  start-page: 120
  year: 2012
  end-page: 7.e2
  ident: r019
  article-title: A free retinal pigment epithelium-choroid graft in patients with exudative age-related macular degeneration: results up to 7 years.
  publication-title: Am J Ophthalmol
– volume: 102
  start-page: 1450
  year: 1995
  end-page: 1460
  ident: r004
  article-title: Prevalence of age-related maculopathy in Australia: the Blue Mountains Eye Study.
  publication-title: Ophthalmology
– volume: 99
  start-page: 11393
  year: 2002
  end-page: 11398
  ident: r008
  article-title: VEGF-Trap: a VEGF blocker with potent antitumor effects.
  publication-title: Proc Natl Acad Sci U S A
– volume: 245
  start-page: 490
  year: 2007
  end-page: 501
  ident: r012
  article-title: The end of submacular surgery for age-related macular degeneration? A meta-analysis.
  publication-title: Graefes Arch Clin Exp Ophthalmol
– volume: 385
  start-page: 509
  year: 2015
  end-page: 516
  ident: r021
  article-title: Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt’s macular dystrophy: follow-up of two open-label phase 1/2 studies.
  publication-title: Lancet
– volume: 88
  start-page: 110
  year: 2004
  end-page: 113
  ident: r016
  article-title: Autologous peripheral retinal pigment epithelium translocation in patients with subfoveal neovascular membranes.
  publication-title: Br J Ophthalmol
– volume: 458
  start-page: 126
  year: 2009
  end-page: 131
  ident: r024
  article-title: Generation of retinal cells from mouse and human induced pluripotent stem cells.
  publication-title: Neurosci Lett
– volume: 99
  start-page: 933
  year: 1992
  end-page: 943
  ident: r002
  article-title: Prevalence of age-related maculopathy: the Beaver Dam Eye Study.
  publication-title: Ophthalmology
– volume: 95
  start-page: 370
  year: 2011
  end-page: 375
  ident: r020
  article-title: Human retinal pigment epithelium (RPE) transplantation: outcome after autologous RPE-choroid sheet and RPE cell-suspension in a randomised clinical study.
  publication-title: Br J Ophthalmol
– volume: 136
  start-page: 688
  year: 2003
  end-page: 695
  ident: r017
  article-title: Autologous retinal pigment epithelium and choroid translocation in patients with exudative age-related macular degeneration: short-term follow-up.
  publication-title: Am J Ophthalmol
– volume: 137
  start-page: 504
  year: 2004
  end-page: 510
  ident: r006
  article-title: Pathogenesis of lesions in late age-related macular disease.
  publication-title: Am J Ophthalmol
– volume: 113
  start-page: E81
  year: 2016
  end-page: E90
  ident: r030
  article-title: Transplantation of human embryonic stem cell-derived retinal tissue in two primate models of retinal degeneration.
  publication-title: Proc Natl Acad Sci U S A
– volume: 22
  start-page: 102
  year: 1991
  end-page: 108
  ident: r013
  article-title: A technique for retinal pigment epithelium transplantation for age-related macular degeneration secondary to extensive subfoveal scarring.
  publication-title: Ophthalmic Surg
– volume: 4
  start-page: 860
  year: 2015
  end-page: 872
  ident: r023
  article-title: Treatment of macular degeneration using embryonic stem cell-derived retinal pigment epithelium: preliminary results in Asian patients.
  publication-title: Stem Cell Reports
– volume: 45
  start-page: 4151
  year: 2004
  end-page: 4160
  ident: r015
  article-title: Outcome of transplantation of autologous retinal pigment epithelium in age-related macular degeneration: a prospective trial.
  publication-title: Invest Ophthalmol Vis Sci
– volume: 474
  start-page: 212
  year: 2011
  end-page: 215
  ident: r027
  article-title: Immunogenicity of induced pluripotent stem cells.
  publication-title: Nature
– volume: 2
  start-page: 662
  year: 2014
  end-page: 674
  ident: r029
  article-title: Transplantation of embryonic and induced pluripotent stem cell-derived 3D retinal sheets into retinal degenerative mice.
  publication-title: Stem Cell Reports
– volume: 112
  start-page: 500
  year: 1994
  end-page: 509
  ident: r010
  article-title: Laser photocoagulation for juxtafoveal choroidal neovascularization: five-year results from randomized clinical trials.
  publication-title: Arch Ophthalmol ;Macular Photocoagulation Study Group
– volume: 85
  start-page: 1153
  year: 2001
  end-page: 1157
  ident: r005
  article-title: Prevalence of age related maculopathy in a representative Japanese population: the Hisayama study.
  publication-title: Br J Ophthalmol
– volume: 355
  start-page: 1419
  year: 2006
  end-page: 1431
  ident: r007
  article-title: Ranibizumab for neovascular age-related macular degeneration.
  publication-title: N Engl J Med
– volume: 379
  start-page: 713
  year: 2012
  end-page: 720
  ident: r022
  article-title: Embryonic stem cell trials for macular degeneration: a preliminary report.
  publication-title: Lancet
– volume: 2
  start-page: 205
  year: 2014
  end-page: 218
  ident: r025
  article-title: Characterization of human induced pluripotent stem cell-derived retinal pigment epithelium cell sheets aiming for clinical application.
  publication-title: Stem Cell Reports
– volume: 342
  start-page: 483
  year: 2000
  end-page: 492
  ident: r001
  article-title: Age-related macular degeneration.
  publication-title: N Engl J Med
– volume: 111
  start-page: 1967
  year: 2004
  end-page: 1980
  ident: r011
  article-title: Surgery for subfoveal choroidal neovascularization in age-related macular degeneration: ophthalmic findings: SST report no. 11.
  publication-title: Ophthalmology
– volume: 120
  start-page: 2292
  year: 2013
  end-page: 2299
  ident: r009
  article-title: Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP).
  publication-title: Ophthalmology ;SEVEN-UP Study Group
– volume: 9
  start-page: 217
  year: 1999
  end-page: 230
  ident: r014
  article-title: Long-term outcome of RPE allografts in non-immunosuppressed patients with AMD.
  publication-title: Eur J Ophthalmol
– volume: 56
  start-page: 1051
  year: 2015
  end-page: 1062
  ident: r028
  article-title: Inhibition of T-cell activation by retinal pigment epithelial cells derived from induced pluripotent stem cells.
  publication-title: Invest Ophthalmol Vis Sci
– ident: r015
  doi: 10.1167/iovs.04-0118
– ident: r003
  doi: 10.1016/S0161-6420(95)31034-2
– ident: r004
  doi: 10.1016/S0161-6420(95)30846-9
– ident: r007
  doi: 10.1056/NEJMoa054481
– ident: r009
  doi: 10.1016/j.ophtha.2013.03.046
– ident: r029
  doi: 10.1016/j.stemcr.2014.03.011
– volume: 22
  start-page: 102
  year: 1991
  ident: r013
  publication-title: Ophthalmic Surg
– ident: r016
  doi: 10.1136/bjo.88.1.110
– ident: r031
  doi: 10.1371/journal.pone.0037342
– ident: r026
  doi: 10.1001/archophthalmol.2009.326
– ident: r028
  doi: 10.1167/iovs.14-15619
– ident: r025
  doi: 10.1016/j.stemcr.2013.12.007
– ident: r002
  doi: 10.1016/S0161-6420(92)31871-8
– ident: r024
  doi: 10.1016/j.neulet.2009.04.035
– ident: r006
  doi: 10.1016/j.ajo.2003.11.026
– volume: 9
  start-page: 217
  year: 1999
  ident: r014
  publication-title: Eur J Ophthalmol
  doi: 10.1177/112067219900900310
– ident: r011
  doi: 10.1016/j.ophtha.2004.07.021
– ident: r022
  doi: 10.1016/S0140-6736(12)60028-2
– ident: r019
  doi: 10.1016/j.ajo.2011.06.007
– ident: r010
  doi: 10.1001/archopht.1994.01090160076025
– ident: r018
  doi: 10.1038/sj.eye.6702823
– ident: r027
  doi: 10.1038/nature09971
– ident: r001
  doi: 10.1056/NEJM200002173420707
– ident: r012
  doi: 10.1007/s00417-005-0184-3
– ident: r005
  doi: 10.1136/bjo.85.10.1153
– ident: r023
  doi: 10.1016/j.stemcr.2015.04.005
– ident: r030
  doi: 10.1073/pnas.1512590113
– ident: r017
  doi: 10.1016/S0002-9394(03)00384-2
– ident: r008
  doi: 10.1073/pnas.172398299
– ident: r020
  doi: 10.1136/bjo.2009.176305
– ident: r021
  doi: 10.1016/S0140-6736(14)61376-3
– reference: 28836423 - N Engl J Med. ;377(8):792
– reference: 30185969 - Nature. 2018 Sep;561(7721):S1
– reference: 28446683 - Sci Transl Med. 2017 Apr 26;9(387):
SSID ssj0000149
Score 2.6853738
Snippet A goal of regenerative medicine is to use induced pluripotent stem cells to generate an autologous graft for transplantation. This study tests the feasibility...
We assessed the feasibility of transplanting a sheet of retinal pigment epithelial (RPE) cells differentiated from induced pluripotent stem cells (iPSCs) in a...
SourceID proquest
pubmed
crossref
mms
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 1038
SubjectTerms Acuity
Age
Aged
Autografts
Biomedical research
Cell Culture Techniques
Cell Differentiation
Clinical trials
Developmental biology
Edema
Feasibility Studies
Female
Fibroblasts
Genomes
Grants
Hospitals
Humans
Induced Pluripotent Stem Cells - cytology
Macular degeneration
Macular Degeneration - therapy
Male
Photoreceptors
Pluripotency
R&D
Regenerative medicine
Research & development
Retina
Retinal Pigment Epithelium - cytology
Retinal Pigment Epithelium - transplantation
Skin
Stem cells
Surgery
Transplantation
Transplantation, Autologous
Vascular endothelial growth factor
Title Autologous Induced Stem-Cell–Derived Retinal Cells for Macular Degeneration
URI https://nejm.org/doi/full/10.1056/NEJMoa1608368
https://www.ncbi.nlm.nih.gov/pubmed/28296613
https://www.proquest.com/docview/1891886882
https://www.proquest.com/docview/1878179668
Volume 376
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1bS8MwFA5eQHwR787LqCA-Gba0TZo-ydwmIkxkKuytJGkqyNpNt_nsf_Af-ks8p8umPsyXPqSHUHKSnO9c-h1CzrhvgrrimmKEn4ZSx1SB1aIm86MsYwpseMn2eSdunsLbHu-5gNvIlVXO7sTyok4HBmPkNSZjJqUAQHg5fKXYNQqzq66FxjJZReoyLOmKetEv-igHf10EyXFsgs2vYaf5gWICyZnlH5u0nOejxXCzNDvXm2TD4UWvMVXwFlmyxTZZ67iM-A7pNCZlB1pw4D1sw2Fs6j2MbU6btt__-vhswQ57h7Eu_toME-HwyAOk6nVUWYLqtexzST2NGtolT9ftx-YNdS0SqAHkM6YpuF9Sp5ybKNLCGAboP4wzzlVs0kzZiMeCp6Hvx8IHx8wge34aWHAdbSCY4MEeWSkGhT0gHjOBzoIwCEOtQu0rLTizqeYsY7JuVVwhF7NFSozjD8c2Fv2kzGNzkfxZ0wo5n4sPp8QZiwSrsOJJYV_yRQLHM2Uk7oCNkp_tUCGn89dwNDDfoQoLqw4ykYT7RuAU-1Mlzj8FE8gATYLD_yc_Ius-2nEs4BPHZGX8NrEngELGulpuNXjKJquS1av23X33Gx1E2Zg
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3NbtQwEB6VrQS9IP67UEqQgBNWa8d2kkOFSrfVlnZXqLRSb8F2HCS0my1kF8St78B78FA8CTNZZ6GH5darM7Ki8XjmG4_9DcALJVy8bZRldMLPZGozZjBqMVeKpCy5wRjesH0Odf9MvjtX5yvwq30LQ9cqW5_YOOpi4uiMfIunGU9TjYDwzcUXRl2jqLrattCYm8WR__EdU7Z657CH6_tSiIP9070-C10FmEOwMGUFZiypLZRySWK1cxwBs8xKpUzmitL4RGVaFVKITAvMZRwRzhexx2zLx5pr6hKBLn9VxpjKdGD17f7w_ck_hFUBcIczq8DqiShji3rbTwzXRAedXomCN8bjejnAbQLdwR24HRBqtDs3qbuw4qt7cHMQavD3YbA7a3reTmZ1RI0_nC-iD1M_Znt-NPp9-bOHNv0Nx07oMTVORMN1hNg4Gpjm0mvU858asmuyiQdwdi3qewidalL5dYi4i20Zy1hKa6QVxmrFfWEVL3m67U3WhdetknIXGMupccYobyrnSudXdNqFVwvxizlVxzLBTdR4XvnP42UCG-1i5GFL1_lfA-zC88Vn3IxUYTGVR62jTJKih9M0xaP5Ii5-hUrWCIbix_-f_Bnc6p8OjvPjw-HRE1gThCLo-qDegM7068w_RQw0tZvB8CL4eN22_gfeWhPP
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3NbhMxEB6VIFVcEH8taUPZSi2nWqm9a-_uAaGqIeoPqRBQKbet7fUioWTTdhMQN96hb9PH4UmY2XgDPYRbr17LWo3HM994xt8A7Ehhw30tDaMbfhYlJmUavRazhYiLgmv04TXb55k6Oo9OhnK4ArfNWxgqq2xsYm2o84mlO_IuT1KeJAoBYbfwZREfe_13l1eMOkhRprVppzFXkVP38weGb9Xb4x7u9a4Q_fdfDo-Y7zDALAKHKcsxeklMLqWNY6Os5Qieo7SQUqc2L7SLZapkHgmRKoFxjSXy-Tx0GHm5UHFFHSPQ_D-MQ8npjMXD-B_qKg-9_e2V5_dEvNGlLvcTzRURQyd3_OGD8bhaDnVrl9d_Ao89Vg0O5sr1FFZc-QxWBz4b_xwGB7O6--1kVgXUAsS6PPg8dWN26Eaj379ueqjd33HsEz2rxoVouAoQJQcDXZe_Bj33taa9Ju14Aef3Irw1aJWT0r2EgNvQFGEURpHRkRHaKMldbiQveLLvdNqGvUZImfXc5dRCY5TVOXSpsjsybcObxfTLOWnHsolbKPGsdN_GyyZ0ms3I_OGusr-q2IbtxWc8lpRr0aVDqeOcOEFbp2iJ9fkmLn6FktcIi8KN_y_-GlZRw7MPx2enm_BIEJygOkLVgdb0euZeIRiamq1a6wK4uG81_wP9uBaf
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Autologous+Induced+Stem-Cell-Derived+Retinal+Cells+for+Macular+Degeneration&rft.jtitle=The+New+England+journal+of+medicine&rft.au=Mandai%2C+Michiko&rft.au=Watanabe%2C+Akira&rft.au=Kurimoto%2C+Yasuo&rft.au=Hirami%2C+Yasuhiko&rft.date=2017-03-16&rft.issn=1533-4406&rft.eissn=1533-4406&rft.volume=376&rft.issue=11&rft.spage=1038&rft_id=info:doi/10.1056%2FNEJMoa1608368&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0028-4793&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0028-4793&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0028-4793&client=summon